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ABSTRACT 
Proper synthesis and targeting of membrane proteins that contain hydrophobic 
transmembrane domains are mediated by chaperones and targeting factors. Tail-anchored 
(TA) proteins are a special class of membrane proteins that are characterized by a single 
carboxy (C) terminal helix that anchors them to biological membranes. Fungal Guided 
Entry of Tail-anchored protein (GET) pathway components, which include four soluble 
proteins—Sgt2, Get3, Get4, Get5—and two membrane bound receptors—Get1 and Get2—
mediate TA biogenesis. These proteins maintain TA protein solubility in the aqueous 
cytosol and target TA to the endoplasmic reticulum. While most of the components are 
conserved in metazoans, one additional protein, Bag6, reorganizes the sorting complex 
from the heterotetrameric Get4-5 to the heterotrimeric Bag6-TRC35-Ubl4A. To understand 
the molecular architecture and mechanism of the Bag6 complex, we took a 
multidisciplinary approach that combines x-ray crystallography, biochemical 
reconstitution, and cell biology. Our studies demonstrate that the BAG domain of Bag6 is 
not a canonical BAG domain. Instead, main role of the Bag6 ‘mock’ BAG domain is to 
dimerize with Ubl4A. Furthermore, the truncated Bag6 complex defined in this study is 
sufficient to facilitate substrate transfer from SGTA to TRC40. Lastly, our results 
unequivocally establish TRC35 as a cytoplasmic retention factor for Bag6. These results 
provide structural, biochemical and cell biological bases for modular Bag6 function and 
regulation of nucleocytoplasmic distribution of Bag6 by TRC35.  
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C h a p t e r  1  
INTRODUCTION 
Biological Membranes and Cellular Evolution 
Formation of the biological membrane was crucial to the emergence of cellular life on 
earth. While it is likely that the first cellular membranes differed significantly from the 
phospholipid bilayers we observe in modern cells, the fundamental properties that 
membranes confer to life do not change. Membranes encapsulate the cell, forming a 
protective barrier from the changing and often harsh environment. This encapsulation also 
results in compartmentalization of the biochemical activity of a cell, such as DNA 
replication and metabolic activity, from the environment. These two conditions were 
prerequisites to the emergence of the self-replicative cell that comprises life on earth today.  
Encapsulation and compartmentalization by biological membranes are also guiding 
principles for achieving further biological complexity in eukaryotes. Membrane bound 
compartments within the plasma membrane partitions specific activities within the cell. 
The encapsulation of DNA by the nuclear membrane, for example, not only ensures greater 
integrity of the cell’s genetic material, but also physically separates transcription from 
translation. This decoupling allows for mRNA processing prior to translation, which 
expands the transcriptome and the proteome without altering the genome size. Other 
subcellular compartments specialize in different functions, such as protein synthesis and 
modification in the case of endoplasmic reticulum (ER) and metabolic reactions in the case 
of mitochondria. In complex multicellular organisms, differential distribution of subcellular 
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organelles in distinct cell types plays a role in determining tissue-specific function. The 
extensive ER networks in pancreatic cells that secrete digestive enzymes and the 
abundance of mitochondria in muscle cells exemplify membrane-bound organelle-driven 
tissue specialization.  
Understanding the molecular machineries that have evolved to accommodate and maintain 
these increasingly complex biological membrane systems is crucial to advancing our 
understanding of cellular biology and can provide valuable insight into the underlying 
principles of molecular evolution. This dissertation explores a metazoan molecular 
machinery involved in proper biosynthesis of proteins that reside in the membrane. 
Membrane Protein Biogenesis 
Biological membranes do not exist in isolation; rather, membrane proteins that reside in 
biological membranes are indispensable for cellular homeostasis, membrane function and 
organelle function (Engel and Gaub, 2008; Tan et al., 2008). Membrane protein synthesis, 
however, is inherently problematic for the cell. First, membrane proteins are characterized 
by hydrophobic transmembrane domains that are required for spanning the hydrophobic 
phospholipid bilayer. Due to these hydrophobic domains, membrane proteins are prone to 
aggregation in the aqueous and crowded cytosol where they are synthesized. Furthermore, 
they need to be targeted to appropriate destination membranes. Dedicated cellular 
machineries work to ensure proper folding and targeting of membrane proteins. One such 
machinery is the universally conserved and essential Signal Recognition Particle (SRP) 
(Akopian et al., 2013). SRP co-translationally recognizes the amino-terminal (N-terminal) 
signal sequence (Blobel and Dobberstein, 1975), which is usually the first transmembrane 
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domain encoded by transmembrane proteins. In eukaryotes, SRP binds the ribosome 
nascent chain complex (RNC) (Walter and Blobel, 1981), and the SRP-RNC complex is 
recruited to the ER membrane via its interaction with the ER-resident SRP receptor (SR) 
(Gilmore et al., 1982). Upon arrival, the RNC is transferred to the Sec61 translocon (Simon 
and Blobel, 1991), a protein channel through which polypeptides are translocated across 
membranes. In this highly-coordinated process, SRP acts both as a chaperone and a 
targeting factor (Akopian et al., 2013).   
Notably, membrane proteins whose single transmembrane domain is near the carboxy 
terminus (C-terminus) cannot access the co-translational SRP pathway because the 
transmembrane domain—the signal sequence—does not emerge from the ribosome until 
translation has terminated. These proteins, named tail-anchored (TA) proteins, are 
topologically constrained from accessing the SRP pathway. TA proteins were first 
described in 1993 (Kutay et al., 1993). Subsequent biochemical studies showed that the 
post-translational insertion of synaptobrevin, a model TA protein, into the ER membrane is 
SRP-independent and ATP-dependent (Kutay et al., 1995). For 12 years the TA targeting 
machinery remained elusive until a 40 kDa cytosolic ATPase, Transmembrane domain 
Recognition Complex 40 (TRC40), was isolated from an unbiased biochemical screen for a 
predominant TA binding partner in rabbit reticulocyte lysate (Stefanovic and Hegde, 2007).  
Thanks to high evolutionary conservation of TRC40, its fungal counterpart Get3 was 
quickly identified. Get3 was initially identified in a large-scale genetic interaction study of 
the yeast secretory pathway (Schuldiner et al., 2005). Get1, 2, or 3 knockout yeast 
displayed phenotypes consistent with defects in retrograde trafficking, and thus were 
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named Golgi ER Trafficking 1-3 (Schuldiner et al., 2005).  After studies in the mammalian 
TA targeting pathway identified Get3 as the TRC40 homologue (Stefanovic and Hegde, 
2007), Get3 and its membrane associated interaction partners, Get1 and Get2, were re-
established as central players in fungal TA targeting (Schuldiner et al., 2008; Wang et al., 
2011a), which led to the renaming of the Get pathway as Guided Entry of Tail-anchored 
protein pathway. 
 
Figure 1. Overview of the TA targeting pathways in fungi and mammals. Upon translation termination and release 
from the ribosome, TA is captured by Sgt2/SGTA and handed off to Get3/TRC40. This handoff step is facilitated by 
the Get4-5 heterotetramer in yeast and the Bag6 heterotrimer in mammals. The Get3-TA/TRC40-TA complex that 
results is ultimately recruited to the ER membrane by membrane receptors, fungal Get1/2 or mammalian WRB/CAML.  
Unlike the co-translational SRP pathway, which is comprised of a single cytosolic factor 
SRP and a single membrane receptor SR, the fungal Get system is composed of four 
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soluble components—Sgt2, Get3-5—and two membrane bound factors—Get1 and Get2; 
in metazoans, incorporation of one additional soluble factor results in five soluble 
components—SGTA, TRC40, TRC35, Ubl4A, Bag6—and two membrane bound factors—
WRB and CAML. In yeast, upon termination of translation and release from the ribosome, 
TA substrate is captured by Sgt2. Sgt2 hands the TA substrate off to the targeting factor 
Get3 (Wang et al., 2010; Wang et al., 2011a), a process facilitated by the Get4-5 
heterotetramer (Gristick et al., 2014). This Get4-5 heterotetramer will be referred to as the 
fungal sorting complex throughout the text. The Get3-TA complex is recruited to the ER 
membrane via the ER membrane-associated Get3 receptor, Get1/2 complex, followed by 
TA release and insertion into the membrane (Stefer et al., 2011; Wang et al., 2014a).  
In mammals, the overall TA transfer from the Sgt2 homologue, SGTA, to the Get3 
homologue, TRC40, is conserved. SGTA post-translationally captures free TA substrate 
then hands it off to TRC40, a process facilitated by the mammalian sorting complex, the 
Bag6 heterotrimer comprised of Bag6, TRC35 (Get4 homologue) and Ubl4A (Get5 
homologue) (Mariappan et al., 2011; Mock et al., 2015; Stefanovic and Hegde, 2007). The 
TRC40-TA complex is targeted to the ER membrane via its ER receptor, the WRB/CAML 
complex, followed by substrate release and insertion into the membrane (Vilardi et al., 
2011; Vilardi et al., 2014; Yamamoto and Sakisaka, 2012). The incorporation of Bag6 into 
the mammalian TA targeting pathway results in substantial reorganization of the molecular 
architecture of the sorting complex. In yeast, the N-terminal domain of Get5 forms a direct 
complex with the C-terminal binding groove of Get4 (Chartron et al., 2010). Get5 also 
contains a homodimerization domain at its C-terminus (Chartron et al., 2012c). 
  
6 
Bcl-2 associated Athanogene 6 (Bag6, also known as Scythe or BAT3)  
Bag6 is a uniquely metazoan protein that appears late in opisthokont evolution (Fig. 2.11). 
Opisthokonts include a broad range of eukaryotes: the metazoan, choanozoan and fungal 
lineages. The term opisthokont was first coined in 1987 by Thomas Cavalier-Smith (British 
Mycological Society. Symposium (1986 : University of Bristol) et al., 1987), who 
suggested a close evolutionary relationship between fungi and metazoans; analysis of 16S-
like rRNA sequences (Wainright et al., 1993) and key protein sequences (Baldauf and 
Palmer, 1993) confirmed the hypothesis. A commonly isolated isoform of Bag6 is ~130 
kDa with an N-terminal ubiquitin-like (UBL) domain, a large predicted-to-be disordered 
proline-rich domain and a C-terminal putative BAG domain (Fig. 6.2).  
Bag6 was initially described as part of the gene cluster that included the human major 
histocompatibility complex (MHC) class III on chromosome 6, resulting in its first name, 
HLA (human leukocyte antigen)-B-Associated Transcript 3 (BAT3). The genomic 
localization suggested a role in immune response, which has been supported by evidence of 
Bag6 involvement in TH1 cell survival (Rangachari et al., 2012), natural killer cell 
cytotoxicity (Pogge von Strandmann et al., 2007), and MHC class II molecule presentation 
(Kamper et al., 2012a; Pai et al., 2002).  
Based on limited sequence homology to the Bcl-2 associated Athanogene (BAG) family 
and apparent Hsc70 regulating activity, BAT3 was renamed Bag6 in 2001 (Thress et al., 
2001). BAG family of proteins are multidomain proteins characterized by a conserved C-
terminal BAG domain (Qin et al., 2016; Takayama and Reed, 2001). The BAG domain is 
usually 110 to 130 residues long and folds into a three helix bundle that acts as a nucleotide 
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exchange factor for Hsp70 family of chaperones (Arakawa et al., 2010; Briknarova et al., 
2001). Excess BAG domain has been shown to inhibit Hsc70 refolding activity in vitro 
(Takayama et al., 1997). Initial searches that identified four additional functional 
homologues of Bag1 (Bag2-5) (Takayama et al., 1999) failed to detect Bag6. 
In addition to its roles in immune regulation, there is increasing evidence for nuclear 
functions of Bag6. Bag6 contains a functional nuclear localization sequence (NLS) 
(Manchen and Hubberstey, 2001) and endogenously localizes both in the nucleus and the 
cytoplasm (Kamper et al., 2012b; Manchen and Hubberstey, 2001; Pogge von Strandmann 
et al., 2007; Tsukahara et al., 2009; Wu et al., 2004). Bag6 NLS is removed by apoptosis 
inducers (Preta and Fadeel, 2012a, b) or masked by TRC35 (Wang et al., 2011a). In 
addition, inhibition of Crm1-dependent nuclear export prevents trafficking of Bag6 from 
the nucleus (Kamper et al., 2012b). Nuclear Bag6 has been shown to play a role in DNA 
damage response (Krenciute et al., 2013), p53 acetylation (Sasaki et al., 2007), cell cycle 
regulation (Yong and Wang, 2012), p300-mediated acetylation (Sebti et al., 2014a) and 
histone methylation (Nguyen et al., 2008; Wakeman et al., 2012). Secreted forms of Bag6 
have also been observed, and which appear to modulate natural killer cell cytotoxicity in 
chronic lymphocytic leukemia patients (Reiners et al., 2013).  
Bag6 has been implicated in a variety of additional cellular processes via numerous binding 
partners such as apoptosis inducing factor (AIF), Reaper, osteopontin, Rpn10c, SGTA, 
gp78, UbxD8, Rpt5, BORIS, SCP and RNF126 (Akahane et al., 2013; Desmots et al., 
2008; Goto et al., 2011; Kikukawa et al., 2005; Long et al., 2012; Nguyen et al., 2008; 
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Rodrigo-Brenni et al., 2014; Thress et al., 2001; Xu et al., 2013) (Fig. 6.2). Importantly, 
multiple studies have independently shown the interaction between components of the TA 
targeting pathway (SGTA, TRC35, Ubl4A) and Bag6, demonstrating that Bag6 exists in 
complex with TR35 and Ubl4A in the cytoplasm (Hessa et al., 2011; Krenciute et al., 2013; 
Mariappan et al., 2010; Mariappan et al., 2011; Wang et al., 2011b), with frequent 
interactions with SGTA (Chartron et al., 2012b; Leznicki and High, 2012; Leznicki et al., 
2013; Winnefeld et al., 2006; Xu et al., 2012). Bag6 has also been demonstrated to homo-
oligomerize in vitro, introducing greater complexity to the system. This builds a picture of 
Bag6 as a central hub for diverse physiological network of proteins. 
Such diverse cellular roles of Bag6 are reflected by its implications in a variety of diseases. 
Mutations of Bag6 are implicated in Kawasaki Syndrome (Hsieh et al., 2010), rheumatoid 
arthritis (Harney et al., 2008), lung cancer (Chen et al., 2014; Etokebe et al., 2015b; Wang 
et al., 2008; Zhao et al., 2014), type 1 diabetes (Degli-Esposti et al., 1992), myasthemia 
gravis, thymus hyperplasia (Vandiedonck et al., 2004) and osteoarthritis (Etokebe et al., 
2015a). Combined, these data establish Bag6 as a critical player in cellular and organismal 
biology. 
In contrast to the complicated plethora of data on the function of Bag6, precise biochemical 
and structural description had been rare when this work was conceived. This dissertation 
focuses on structural and biochemical characterization of a trimeric Bag6 complex that 
includes TRC35 and Ubl4A. Chapter 2 describes the structural characterization of the 
Bag6-Ubl4A complex and the Bag6-TRC35 complex. TRC35 and Ubl4A bind Bag6 at 
  
9 
distinct binding sites; Ubl4A localizes to the putative BAG domain and TRC35 binds at 
the region that includes the NLS of Bag6. The Bag6-Ubl4A structure reveals that the Bag6-
BAG domain does not resemble a canonical BAG domain, establishing Bag6 as a 
misnomer. TRC35 masking NLS provides the structural basis for nucleocytoplasmic 
distribution of Bag6. Chapter 3 describes the biochemical assays used to functionally 
characterize the BAG domain and the isolated minimal Bag6 complex, which includes a 
truncated C-terminal Bag6, truncated TRC35 and full length Ubl4A. An Hsc70 refolding 
assay is used to confirm that the Bag6 “BAG” domain is not a BAG domain. We also 
developed an in vitro TA transfer assay to demonstrate that the minimal Bag6 complex 
identified in this study is sufficient for facilitating TA handoff, establishing it as a TA 
targeting module. In Chapter 4, the regulation of nucleocytoplasmic distribution of Bag6 by 
TRC35 is explored using biochemical and cell biology techniques. Chapter 5 concludes by 
contextualizing the findings of this dissertation in the body of work on protein targeting and 
quality control.  
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C h a p t e r 2  
STRUCTURAL CHARACTERIZATION OF THE BAG6-TRC35-
UBL4A COMPLEX 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of this chapter were first published in 
Mock, J.-Y., Chartron, J.W., Zaslaver, M., Xu, Y., Ye, Y., and Clemons, W.M. Jr. 
(2015) Bag6 complex contains a minimal tail-anchor-targeting module and a mock 
BAG domain. Proc Natl Acad Sci USA. 112(1): 106-11 doi: 10.1073/pnas.1402745112 
Mock, J.-Y., Xu, Y., Ye, Y., and Clemons, W.M. Jr. (2017) Structural basis for regulation 
of nucleocytoplasmic distribution of Bag6. Submitted. 
Jee-Young Mock solved the crystal structures, carried out yeast 2-hybrid analysis, 
biophysical experiments with purified proteins, and sequence analysis.  
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Abstract 
Bcl2-associated athanogene cochaperone 6 (Bag6) is a uniquely metazoan protein 
involved in a diverse array of cellular processes. It is part of the heterotrimeric Bag6 
complex, which also includes ubiquitin-like 4A (Ubl4A) and transmembrane domain 
recognition complex 35 (TRC35). The Bag6 complex plays a central role in the 
mammalian tail-anchor protein targeting pathway, mislocalized protein degradation 
pathway and the endoplasmic reticulum-associated degradation pathway. Here we define 
the architecture of the Bag6 complex, demonstrating that both TRC35 and Ubl4A have 
distinct C-terminal binding sites on Bag6 defining a minimal Bag6 complex. The crystal 
structure of the Bag6-Ubl4A dimer demonstrates that Bag6-BAG is not a canonical BAG 
domain. Instead, its main function is to dimerize with the well-conserved dimerization 
domain of Ubl4A. The crystal structure of Bag6 and its cytoplasmic retention factor 
TRC35 reveals remarkable structural conservation of Get4/TRC35 throughout opisthokont 
lineage except at the C-terminal Bag6-binding groove, which diverged to accommodate 
Bag6. Together these data advance our molecular understanding of the Bag6-TRC35-
Ubl4A complex. 
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Introduction 
Bcl2-associated athanogene cochaperone 6 (Bag6, also known as “BAT3” or “Scythe”) 
plays a central role in membrane protein quality control, with additional links to 
apoptosis, transcription regulation, and immunoregulation (for reviews, see (Kawahara et 
al., 2013; Krenciute et al., 2013; Lee and Ye, 2013)). Recent studies demonstrated that 
Bag6 forms a heterotrimeric Bag6 complex with ubiquitin-like 4A (Ubl4A) and 
transmembrane domain recognition complex 35 (TRC35) that determines the fate of 
membrane proteins (Mariappan et al., 2011; Wang et al., 2011b) in tail-anchor (TA) 
protein targeting (Stefanovic and Hegde, 2007), mislocalized protein degradation (Hessa 
et al., 2011), and endoplasmic reticulum (ER)-associated protein degradation (Wang et 
al., 2011b). The many roles of the Bag6 complex likely are centered on its ability to bind 
exposed hydrophobic regions of proteins, such as transmembrane domains.  
In mammals, Bag6 has been shown to be critical in the targeting of TA proteins to the ER 
by the transmembrane recognition complex (TRC) pathway (Mariappan et al., 2011), a 
process best understood in the equivalent fungal guided entry of tail-anchored proteins 
(GET) pathway (Chartron et al., 2012a; Hegde and Keenan, 2011). Although Bag6 is 
absent in fungi, the analogous yeast complex contains two proteins, Get4 and 
Get5/Mdy2, which are homologues of the mammalian proteins TRC35 and Ubl4A, 
respectively. In yeast, these two proteins form a heterotetramer that regulates the handoff 
of the TA protein from the cochaperone small, glutamine-rich, tetratricopeptide repeat 
protein 2 (Sgt2) [small glutamine-rich tetratricopeptide repeat-containing protein (SGTA) 
in mammals] to the delivery factor Get3 (TRC40 in mammals) (Chartron et al., 2010; 
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Chartron et al., 2012c; Gristick et al., 2014; Wang et al., 2010). It is expected that the 
mammalian homologs, along with Bag6, play a similar role (Chartron et al., 2012b; 
Leznicki and High, 2012; Leznicki et al., 2013; Xu et al., 2012).  
Bag6 also interacts with other proteins such as apoptosis-inducing factor, glycoprotein 78 
(gp78), regulatory particle 5, and brother of regulator of imprinted sites (BORIS) 
(Akahane et al., 2013; Desmots et al., 2008; Kikukawa et al., 2005; Long et al., 2012; 
Nguyen et al., 2008; Thress et al., 2001; Xu et al., 2013) and can homo-oligomerize (Xu 
et al., 2013). These findings build a picture of Bag6 as a central scaffolding factor linking 
various cellular processes. A variety of diseases, ranging from cancer to autoimmune 
disorders and diabetes, are linked to Bag6 (Degli-Esposti et al., 1992; Harney et al., 2008; 
Hsieh et al., 2010; Vandiedonck et al., 2004; Wang et al., 2008).  
Despite this demonstrated importance, structural characterization of the Bag6 complex is 
lacking. The longest and most common isoform of the Bag6 gene encodes an 1,132-aa 
protein (Banerji et al., 1990) with an N-terminal ubiquitin-like (UBL) domain that has 
been characterized structurally (PDB ID codes 4EEW, 4DWF, and 1WX9), a large 
proline-rich central domain that is predicted to be unstructured, and a C-terminal 
predicted BAG domain (Bag6-BAG).  
In this study, we map the TRC35- and Ubl4A-binding regions to the C terminus of Bag6. 
Based on these results, the structure of the complex between the heterodimerization 
domains of Bag6 and Ubl4A was solved, revealing unexpected structural homology to 
Get5 and showing that the Bag6-BAG is a “mock” BAG domain. The structure of the 
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complex between the heterodimer of Bag6 and TRC35 presented here provides a 
structural basis for regulation of nucleocytoplasmic distribution of Bag6 by TRC35. 
Furthermore, the structures reveal that despite the changes in architecture, the overall 
folds of the TA sorting complex have been remarkably conserved throughout opisthokont 
evolution.  
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Results 
TRC35 binds the Bag6 nuclear localization sequence, whereas Ubl4A binds the BAG 
domain 
To define the molecular architecture of the heterotrimeric Bag6 complex (Bag6, Ubl4A, 
and TRC35), a series of yeast two-hybrid assays were performed. Bag6 was divided into 
five fragments: A (amino acids 1–225), B (amino acids 226–399), C (amino acids 400–
659), D (amino acids 660–950), and E (amino acids 951–1,126), with the activating 
domain attached at the N terminus (Fig. 2.1A); TRC35 or Ubl4A contained N-terminal 
DNA-binding domains. TRC35 and Ubl4A both showed a positive interaction with the 
C-terminal Bag6E fragment that contains the nuclear localization sequence (NLS) and the 
BAG domain (Fig. 2.1B). To refine the interfaces, Bag6E was divided further into an N-
terminal domain, an NLS domain, and the putative BAG domain (EN, ENLS, and EBAG 
respectively) (Fig. 2.1A). TRC35 showed an interaction with ENLS (Fig. 2.1B) confirming 
the in vivo result that TRC35 masks the Bag6-NLS, preventing nuclear targeting (Wang 
et al., 2011b). Ubl4A showed an interaction with EBAG (Fig. 2.1B), a surprising result 
because none of the five previously characterized BAG domains was known to form 
stable interactions with other proteins.  
According to sequence alignment, Ubl4A lacks the Get5 N-terminal domain, and TRC35 
lacks the β-loop in Get4 (Fig. 2.2A), both of which are involved in the Get4 interface 
with Get5 (Chartron et al., 2010). This difference suggests there are different interactions 
in the Bag6 complex. One possibility is that the region around the Bag6 NLS acts 
structurally like the Get5 N domain by binding the C domain of TRC35. To confirm this 
hypothesis, a two-hybrid experiment was performed with TRC35 split into either an N 
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domain (TRC35-N, residues 1–157) or a C domain (TRC35-C, residues 158–327), as 
had been done previously for Get4 (Fig. 2.2A) (Chang et al., 2010). As predicted, Bag6E 
showed a clear interaction with TRC35-C and no interaction with TRC35-N (Fig. 2.2B). 
Surprisingly, the smaller Bag6ENLS did not interact with TRC35-C (Fig. 2.2B) despite the 
previously seen interaction with full-length TRC35 (Fig. 2.1B). This interaction was 
restored with the longer Bag6EN,NLS, suggesting that additional contacts are required to 
form a stable interaction. This extended region defines a minimal complex with TRC35 
bound to the C terminus of Bag6 in close proximity to Ubl4A, similar to the architecture 
found in the yeast Get4-5 complex.  
The crystal structure of Bag6-BAG/Ubl4AC 
For structural characterization, multiple variants of the Bag6min complex were pursued for 
crystallization. One consisting of the Ubl4A C-terminal dimerization domain (Ubl4A-C) 
and the Bag6 BAG domain (Bag6-BAG, residues 1054-1107) resulted in well-formed 
crystals. A complete 2.1 Å native data set was collected in the space group P21 and 
phased using an iodide derivative. The final refinement resulted in an Rfree of 28.0% and 
good statistics (Table 2.1). Both domains are primarily helical (Fig. 2.3A) with an 
extensive dimer interface dominated by conserved hydrophobic residues that results in 
2485 Å2 of buried surface (Fig. 2.3A). Bag6-BAG contains three helices in an extended 
conformation making few intramolecular contacts. Ubl4A-C contains three helices with 
the first two forming an interface and the short third helix wrapping around Bag6-BAG 
(Fig. 2.3A). All of the conserved hydrophobic residues of Bag6-BAG participate in 
dimerization (Fig. 2.3B). 
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While fungal Get5 forms a stable homo-dimer mediated by Get5-C, Ubl4A alone is 
primarily a monomer (Chartron et al., 2012c). As Ubl4A forms a hetero-dimer with Bag6 
one might expect a novel fold for Ubl4A-C; instead, the Ubl4A-C hetero-dimerization 
domain has an identical structure to the Get5-C homo-dimerization domain, an RMSD of 
0.94 Å for equivalent backbone residues (Figs. 2.4A and B). The same hydrophobic 
residues that form the core in Get5 homo-dimerization—W179, I182, L186, F190, V200, 
L204, W208—are conserved in Ubl4A—W96, I99, L103, F107, V115, L119, Y123 
(Figs. 2.4B and C). 
Bag6-BAG is a ‘mock’ BAG domain 
Based on the structural characterization, the Bag6-BAG is shorter (47 residues) than 
canonical BAG domains (6-112 residues) and the three helices do not form a BAG-like 
three-helix bundle, with different orientations of the few residues equivalent to those 
involved in Hsp70 binding of other BAG domains (Figs. 2.5A and B).  
Furthermore, circular dichroism of Bag6-BAG alone indicates no stable secondary 
structure (Fig. 2.6). This implies that a primary role for Bag6-BAG is to hetero-dimerize 
with Ubl4A, as the two are found in a stoichiometric complex (Hessa et al., 2011; 
Mariappan et al., 2010). 
The crystal structure of Bag6-NLS/TRC35 complex 
A complex between TRC35 (residues 23 to 305) and a minimal TRC35-binding domain 
of Bag6 that contains the NLS (residues 1000-1054) was co-expressed, purified and 
crystallized. A dataset from a single crystal was collected to 1.8Å resolution and phases 
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were obtained using single wavelength anomalous dispersion from a rubidium 
derivative. The final model refined to 1.8 - 40Å had good statistics with an Rwork=16.5% 
and an Rfree=20.1% and no residues in the disallowed region of the Ramachandran. Full 
crystallographic statistics are provided in Table 2.2. All TRC35 residues in the 
crystallized construct were visible in the electron density except for S137 and G138 that 
are disordered in the loop between α6 and α7. For Bag6, residues 1002-1043 were 
resolved with only a few terminal residues ambiguous in the electron density. 
TRC35 has the same overall architecture as the fungal Get4 structures (Fig. 2.8A), 
revealing that the Get4 fold has been conserved across opisthokonta and is likely 
conserved across all eukaryotes. Opisthokonta includes metazoan, choanozoan, and 
fungal lineages (Fig. 2.11), which share common ancestry as determined by analysis of 
16S-like rRNA sequences (Wainright et al., 1993) and several protein sequences (Baldauf 
and Palmer, 1993). The first 15 α-helices form an α-solenoid fold that can be divided into 
an N- and C-terminal halves (Fig. 2.7). Alignment of the NTD between TRC35 and Get4 
(PDB ID: 3LKU) results in an RMSD = 1.380Å for that region, while the equivalent 
alignment in the CTD results in an RMSD = 3.429Å (Fig. 2.8). As seen in Get4 (Chartron 
et al., 2010), there is likely some flexibility between these two halves based on 
differences across crystal forms. As predicted from sequence alignment analysis, the β-
hairpin in Get4 is replaced by a shorter loop in TRC35 (Fig. 2.7C, arrows). The C-
terminal α16 is flanked by two extended stretches that cover part of Bag6 (Fig. 2.7A). 
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The Bag6 NLS region wraps around the TRC35-CTD (Fig. 2.7B, light pink) at an 
interface that resembles the interaction of Get5 with Get4 (Fig. 2.7C). The interaction is 
stabilized by two hydrophobic interface sites. In interface I, Bag6 α1 and α2 dock into a 
conserved pocket created by α12 and α13 of TRC35 (Fig. 2.9B) and include W1004, 
V1008 and W1012 from Bag6 and V254, V257, F242, L258 and Y262 from TRC35 (Fig. 
2.7E). In fungal Get4-5, the Get5 N-terminal helix docks into a groove formed by α12, 
α13, and the β-hairpin of Get4 (Fig. 2.7C). The missing β-hairpin in TRC35 results in the 
Bag6 helix shifting away from α11 towards α12 and α13 near the bottom of TRC35 (Fig. 
2.7C, arrows). The differences in the interface result in changes in the arrangement of 
α11, α13, and α15 of TRC35 (Fig. 2.7C) relative to those of Get4. Interface II is less 
extensive involving fewer residues, L1032, Y1036, M1040 of Bag6 and F195, M271 of 
TRC35 (Fig. 2.7E). While the connecting loops between the two interfaces are well-
ordered in both contexts, the Bag6 loop makes fewer contacts to TRC35 than the 
extensive interactions in the Get5-loop to Get4 (Fig. 2.7B). 
The structure reveals how TRC35 masks the Bag6 bipartite NLS (Fig. 2.7B). The 
conserved first basic cluster of the predicted NLS (K1024RVK) is sequestered between 
interfaces I and II (Fig. 2.7B, sticks). Only the first lysine residue of the second cluster 
(K1043RRK) is resolved in our model (Fig. 2.7B, sticks). The truncated C-terminal 
residues of TRC35 in our construct are predicted to be disordered (Linding et al., 2003) 
and include conserved multiple negative charges (five Glu and three Asp (Fig. 2.10)) that 
would be in position to mask the second NLS basic cluster, K1043RRK, through charge-
mediated interactions. 
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TRC35 and TRC40 are Conserved throughout Opisthokont Evolution 
Unlike Get4, the CTD of TRC35 does not bind the homologous counterpart Ubl4A, and 
the change in binding partner is reflected at the sequence level by the lack of the β-
hairpin in TRC35 and the lack of the N-terminal extension in Ubl4A. We hypothesized 
that the loss of the fungal features may coincide with the appearance of Bag6. To address 
this, we turned to phylogenetic analysis. First, sequence alignments of Bag6, TRC35, 
Ubl4A, SGTA and TRC40 were used to generate sequence motifs using the Multiple Em 
for Motif Elicitation suite (MEME) (Bailey et al., 2009). Species were selected based on 
fully sequenced genomes from representative lineages of Eukaryota. The MEME motifs 
were used to search each of the genomes shown (Fig. 2.11). 
Consistent with our hypothesis, in opisthokonts the split from the fungal lineage 
coincides with disappearance of the Get4/TRC35 β-hairpin (Figs. 2.10 and 2.11) and the 
Get5/Ubl4A N-terminal extension. However, species lacking Get4/TRC35 β-hairpin do 
not immediately gain Bag6. In TA targeting, Bag6 centrally bridges the Ubl4A-mediated 
TA substrate hand-off from SGTA to TRC40 which itself is mediated by TRC35 (Mock 
et al., 2015). Curiously, various lineages seem to lack either Sgt2/SGTA or Get5/Ubl4A 
with Get5/Ubl4A most often missing. In both mammals and yeast, the interaction 
between the two proteins (Chartron et al., 2011) has been demonstrated to be crucial to 
TA protein transfer (Mateja et al., 2015; Mock et al., 2015) and ER-associated 
degradation system (Xu et al., 2013). In species that lack TRC35 β-hairpin, Bag6, and 
Ubl4A, such as Demosponge or Caenorhabditis, it is unclear how these processes are 
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modulated. It is likely that functionally homologous proteins with low sequence 
homology exist.  
Get4/TRC35 and Get3/TRC40 are conserved throughout eukaryotic evolution and seem 
to occur as a pair in all opisthokonts and in most eukaryotes, suggesting the essentiality 
of the two proteins in the pathway. Consistent with this notion, residues at the predicted 
TRC35-TRC40 interface and the TRC35-Bag6 interface in TRC35 are highly conserved 
(Figs. 2.8A and 2.8C). 
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Discussion 
The Bag6 complex has been implicated in various cellular pathways necessitating a 
description of its molecular architecture. In this study, we have examined the Bag6 
trimeric complex and solved high-resolution crystal structures of the Bag6-Ubl4A and 
Bag6-TRC35 complexes.  
The initial characterization of Bag6 BAG domain relied on limited and inaccurate 
sequence homology (Thress et al., 2001) without structural information. Comparison of 
high resolution structures of BAG domains, as well as circular dichroism data that show 
Bag6-BAG alone is intrinsically disordered, suggests that the Bag6-BAG domain is not a 
canonical BAG domain. Biochemical data from the previous study that demonstrated 
functional equivalence between Bag6 BAG and canonical BAG domains will be 
addressed later in this work.  
The first functional annotation of Scythe (the Bag6 Xenopus homolog) was an ability to 
bind Reaper, an apoptosis-inducing protein in Drosophila, thus inhibiting Reaper-induced 
apoptosis in Xenopus oocyte extracts (Thress et al., 1999; Thress et al., 1998). Reaper 
induces apoptosis in a variety of model systems, including Xenopus oocyte extract 
(Evans et al., 1997), SF-21 insect cells (Vucic et al., 1997), and HeLa human cancer cells 
(Tait et al., 2004). Sequence alignment of the conserved Ubl4A dimerization domain and 
Reaper reveals the conservation of most of the residues involved in Bag6-BAG/Ubl4A-C 
dimerization (Fig. 2.4), suggesting that Reaper may disrupt the Bag6/Ubl4A interaction. 
This hypothesis would be consistent with Reaper’s binding the 312-residue C-terminal 
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truncation of Scythe (ScytheC312), leading to the release of bound factors (Thress et al., 
1998). 
The remarkable conservation of TRC35 in both sequence and structure from yeast to 
human can be attributed to the role of TRC35 as a hub of protein-protein interactions in 
the TRC pathway. The most important interaction, based on its complete conservation, is 
between TRC35 and TRC40 (Fig. 2.9) and likely drives evolution of the components in 
the pathway. This interaction is critical for the regulation of TA protein transfer (Gristick 
et al., 2014; Mock et al., 2015; Shao et al., 2017) and, as shown in fungal Get4, for 
release of Get3/TRC40 from the ER membrane to restore the cytosolic pool of complex 
ready for TA protein transfer (Rome et al., 2014). The importance of linking TRC35 
homologs to Ubl4A homologs, while less conserved, is sustained in humans despite the 
loss of structural features that allow these two proteins to interact with each other. In this 
case, a new component Bag6 is introduced, which serves as a scaffold to link TRC35 to 
Ubl4A. The Bag6-TRC35 structure reveals that TRC35 binds this novel binding partner 
utilizing conserved patches in a distinct fashion (Fig. 2.9). This led to the expansion of 
the TRC35 protein-protein interaction network while maintaining its crucial interaction 
with TRC40. Our findings establish support the model in which TRC35 is an important 
hub of a protein-protein interaction network with its interaction with TRC40 at the core. 
Higher eukaryotes expanded on this network by the addition of Bag6. 
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The emergence of Bag6 in metazoan evolution is also an intriguing question. How did 
such a complex and extended scaffolding protein emerge? The exact genetic events are 
difficult to pinpoint because the DNA sequences that can provide clues to events such as 
previous recombination or gene duplication are not under selective pressure, and are 
therefore quickly removed (Moore et al., 2008). Instead, the protein sequence of Bag6 
can be used to speculate the evolutionary origins of Bag6.  
There are evolutionary trends that can be applied to deduce the evolutionary origin of 
Bag6. Bioinformatic survey of multidomain proteins suggest that novel multidomain 
proteins are often created by single domain insertions and deletions at the N- and C- 
termini (Bjorklund et al., 2005; Kummerfeld and Teichmann, 2005). These domain 
rearrangement events seem to occur more frequently in metazoans than in other 
phylogenetic groups (Ekman et al., 2007). Similarly, the N-terminal UBL domain and C-
terminal TRC35 and Ubl4A binding domains are conserved structural elements that could 
have been added through independent domain insertion and rearrangement events. 
A similar phenomenon has been observed in the evolution of the membrane-associated 
guanylate kinase (MAGUK) family of proteins, which are involved in cell-cell 
communication in metazoa. Putative ancestral MAGUK-like genes were discovered in 
unicellular ancestors to metazoans, Capsaspora owczarzaki and Monosiga brevicollis, as 
well as the earliest surviving metazoan Amphimedon queenslandica (de Mendoza et al., 
2010). These ancestral genes contain parts of the domains that have been expanded upon 
in modern MAGUK proteins by domain insertion and rearrangement events. 
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These results support a model in which the primary role of the Bag6 C terminus is to 
bridge TRC35 and Ubl4A. Possible Bag6 dimerization would form a heterohexamer, 
creating a complex analogous to the Get4-5 heterotetramer found in yeast and providing 
strong structural parallels in TA targeting (Fig. 2.12). Several unanswered questions 
about the Bag6 complex remain. Does Bag6-BAG domain behave like a canonical BAG 
domain? Is the structurally characterized Bag6 complex functionally equivalent to the 
fungal Get4-5 complex? Can disrupting the Bag6-TRC35 interface lead to changes in the 
nucleocytoplasmic distribution of Bag6? Biochemical and cell biological methods will be 
used to answer these questions in the following chapters. 
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Figures 
 
Figure 2.1. Bag6 has distinct binding sites for TRC35 and Ubl4A at its C-terminus 
(A) Scheme of the five different Bag6 fragments and of the sub-fragments of Bag6E, which 
is further divided into N-terminus (EN), the NLS (ENLS), and a fragment containing only the 
putative BAG domain (EBAG). (B) Yeast two-hybrid assay between Bag6 fragments and 
either TRC35 or Ubl4A. The A fragment contains the UBL domain and the E fragment 
contains the NLS and putative BAG domain. Yeast two-hybrid assay of TRC35 or Ubl4A 
between the Bag6 E fragments. 
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Figure 2.2 Defining the interaction between Bag6 and TRC35 by yeast two-hybrid 
assay 
(A, Upper) Diagram of the Get4/Get5-N complex (PDB ID code 3LKU). Get4 is shown in 
gray and red, and Get5 is shown in green. (Lower) A top-view schematic representation of 
the architecture. The two β-strands in Get4 that are missing in TRC35 are outlined in blue. 
Ubl4A does not contain a Get5-N equivalent. (B) Bag6E fragments containing the 
activating domain were combined with full-length TRC35 (FL), TRC35-N (residues 1–
157), or TRC35-C (residues 158–327) conjugated to the binding domain. TRC35-N and 
TRC35-C were defined by sequence alignment with Get4. 
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Figure 2.3. Crystal structure of Bag6-BAG/Ubl4A-C heterodimer 
(A) The overall structure of Bag6-BAG/Ubl4A-C heterodimer in ribbon representation 
with Bag6-BAG in cyan and Ubl4A-C in magenta. Hydrophobic residues in Bag6 involved 
in packing are highlighted as orange sticks. (B) Sequence alignment of Bag6-BAG (H.sap 
Homo sapiens, X.tro Xenopus tropicalis, D.mel Drosophila melanogaster, D.rer Danio 
rerio, S.kow Saccoglossus kowalevskii, and T.cas Tribolium castaneum). The secondary 
structure based on the structure is highlighted above the text. The conserved hydrophobic 
and aromatic residues involved in the hydrophobic packing interactions between Bag6-
BAG and Ubl4A-C are highlighted in orange. The extended Drosophila melanogaster 
sequence is a predicted protein sequence based on theoretical translation, and may not 
reflect a physiological isoform. 
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Figure 2.4. Ubl4A-C and Get5-C are structurally homologous 
(A) A monomer of Get5-C (green) (PDBID: 3VEJ) and Ubl4A-C (pink) overlaid. Bag6-
BAG is included in cyan. The inset shows the Get5-C homo-dimer. (B) Ubl4A-C and 
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Get5-C are juxtaposed with conserved residues involved in dimerization highlighted as 
orange sticks. (C) Sequence alignment of Ubl4A-C homologs (H.sap Homo sapiens, D.rer 
Danio rerio, X.tro Xenopus tropicalis, A.fum Aspergillus fumigatus, and S.cer 
Saccharomyces cerevisiae) and the Drosophila apoptosis-inducing protein Reaper. The 
Ubl4A-C and Get5C secondary structure are shown above (pink) and below (green), 
respectively. Conserved hydrophobic residues involved in dimerization are highlighted in 
orange. 
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Figure 2.5. A comparison of Bag6-BAG to canonical BAG domains 
(A) Published structures of BAG domains are shown as ribbons similar to Bag6-BAG. 
Residues involved in Hsp/Hsc70 binding are highlighted as magenta sticks. (B) Sequence 
alignment of human Bag1-BAG, Bag5-BAG5, and Bag6-BAG with known secondary 
structure indicated.  
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Figure 2.6. Circular dichroism spectra of Bag6-BAG, Ubl4A-C and the complex of the 
two 
Spectra for Bag6-BAG (blue), Ubl4A-C (green), and Bag6-BAG/Ubl4A-C (red).  
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Figure 2.7. The crystal structure of the Bag6-NLS/TRC35 heterodimer 
(A) The structure of Saccharomyces cerevisiae Get4-Get5N complex (PDBID: 3LKU), 
Get4 in rainbow and Get5 in magenta. Sequence alignment of TRC35/Get4 from helix 11 
to 12 of two metazoan species, Hsap (Homo sapiens), Aque (Amphimedon queenslandica), 
and six fungal species Spom (Schizosaccharomyces pombe), Ncas (Naumovozyma castelli), 
Scer (Saccharomyces cerevisiae), Afum (Aspergillus fumigatus), Ncra (Neurospora 
crassa), and Smus (Sphaerulina musiva). The secondary structure based on fungal Get4s is 
highlighted above the text. (B) Left, the overall structure of Bag6-TRC35 heterodimer in 
cylinder representation with Bag6 in light pink and TRC35 in rainbow. The nuclear 
localization sequence is highlighted in sticks on Bag6. Right, a 90˚ in plane rotated 
‘bottom’ view. The 16 helices of TRC35 are labeled from N to C terminus. (C) 
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Comparison of the C-terminal faces of TRC35 and Get4 that bind Bag6 and Get5, 
respectively. The arrows highlight the significant structural difference in the residues 
between α11 and α12. (D) Zoomed in view of the regions, defined as interface I and II. 
Hydrophobic residues that are involved in Bag6-TRC35 dimerization are shown as sticks. 
  
  
35 
 
Figure 2.8. Comparison of TRC35 and Get4 structures 
(A) Representative structures of fungal Get4 homologs. 3LKU is from Saccharomyces 
cerevisiae (Sc) and 3LPZ is from Chaetomium thermophilum (Ct). (B) Aligned human 
TRC35 (color ramped) and ScGet4 (3LKU, grey) using Pymol (Schrodinger, 2015) super 
for sequence-independent structural alignment. Left, structures aligned to the six N-
terminal helices. Right, structures aligned to the seven C-terminal helices. 
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Figure 2.9 Analysis of the surface conservation and hydrophobicity of TRC35 
(A) Accessible surface representation of TRC35 colored based on percent conservation as 
implemented in Chimera (Pettersen et al., 2004). Conservation based on a MAFFT (Katoh 
and Standley, 2013) alignment of TRC35/Get4 sequences from Homo sapiens, Xenopus 
laevis, Danio rerio, Drosophila melanogaster, Nematostella vectensis, Monosiga 
brevicollis, Schizosaccharomyces pombe, and Saccharomyces cerevisiae. Bag6 is in 
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ribbons representation in pink. (B) The Bag6-binding surface of TRC35 colored based on 
hydrophobicity (Kyle-Doolittle scale) and percent conservation as implemented in Chimera 
(Pettersen et al., 2004). 
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Figure 2.10. Representative aligned sequences of eukaryotic TRC35/Get4 
Species selected based on the eukaryotic phylogenetic tree by Eme et al (Eme et al., 
2009). Sequences were aligned with MAFFT (Katoh and Standley, 2013). α-helices, 
based on the TRC35 structure, are highlighted in colors that correspond to the crystal 
structure on Figure 2.1B and numbered on top. Residues highlighted in red boxes were 
identified as critical to fungal Get4 binding Get3 (Gristick et al., 2014). Residues 
highlighted in blue boxes are critical to Get4/TRC35 regulating Get3/TRC40 (Gristick et 
al., 2014). The residues that comprise the fungal β-hairpin are highlighted in a black box. 
The arrow indicates the end of the crystallization construct. Purple boxes highlight 
glutamate and aspartate residues in the C-terminus of TRC35.  
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Figure 2.11 Survey of factors involved in the TRC pathway in eukaryotes 
A condensed phylogenetic tree of representative eukaryotes was built based on the 
maximum likelihood phylogenetic tree of eukaryotes by Eme et al (Eme et al., 2014). The 
genome of each organism was searched for the presence of Get4/TRC35, Ubl4A/Get5, 
Sgt2/SGTA, Get3/TRC40, and Bag6 using MEME suite motif discovery tool (MEME) 
(Bailey et al., 2009) and motif scanning tool (MAST) (Bailey and Elkan, 1994) in addition 
to NCBI protein BLAST (Altschul et al., 1990). Proteins are color coded and sequence 
elements are highlighted. Black circles indicate homologs that are missing residues 
demonstrated to be critical in fungal TA-targeting studies.  
  
41 
Table 2.1 Bag6-Ubl4A crystallographic data and model refinement statistics  
 Native Iodide 
Data collection   
Protein Bag6-BAG/Ubl4A-C  Bag6-BAG/Ubl4A-C 
Synchrotron ALS ALS 
Beamline 8.2.1 8.2.1 
Space group P21 P21 
Cell dimensions   
    a, b, c (Å) 47.2, 56.4, 75.5 47.4, 57.2, 75.9 
    a, b, g (°) 90.0, 96.2, 90.0 90.0, 95.9, 90.0 
   
Wavelength 1.0000 1.7000 
Resolution (Å) 28.2 – 2.05 28.6 – 3.5 
Rmerge (%)a 3.6 (71.1) 14.2 (162.6) 
< I > / < sI >a 18.3 (2.0) 24.8 (3.0) 
Completeness (%)a 98.7 (98.3) 99.9 (100.0) 
No. of observations 78,344 258,426 
No. of unique reflections a 26,539 (1,950) 11,271 (1,483) 
Redundancya 3.0 (2.7) 22.9 (23.3) 
 
Refinement   
Resolution (Å) 28.3 – 2.0  
No. of reflections 26525  
No. of reflections test set 1338  
Rwork / Rfree 0.251 (0.335) / 0.280 (0.353)  
No. atoms (non-hydrogen) 3298  
    Protein 3159  
    Water 139  
B-factors   
    Protein 43.60  
    Water 41.80  
RMSD   
    Bond lengths (Å)  0.019  
    Bond angles (°) 1.30  
   
Ramachandran plot   
    Favored (%) 95  
    Additionally allowed (%)   
    Outliers (%) 1.9  
 
aHighest-resolution shell is shown in parentheses 
  
  
42 
Table 2.2 Bag6-TRC35 crystallographic data and model refinement statistics  
 Native  Rubidium 
Data collection   
Protein Bag6-TRC35 Bag6-TRC35 
Synchrotron SSRL SSRL 
Beamline 12-2 12-2 
Space group P21 21 21 P21 21 21 
Cell dimensions   
    a, b, c (Å) 41.7, 84.6, 102.6 42.0, 84.3, 102.5 
    a, b, g (°) 90.0 90.0, 90.0 90.0, 90.0, 90.0 
Wavelength 0.9200 0.8154 
Resolution (Å) 39.1 – 1.80 (1.92 – 1.80) 50.0 – 1.99 (2.11 – 1.99)  
Rmeas (%)a 9.3 (64.3) 16.9 (118.8) 
I  /  s(I)  16.9 (3.8) 14.9 (2.1) 
CC1/2 (%) 99.9 (95) 99.9 (88.0) 
Completeness (%)a 98.7 (92.7) 99.2 (95.6) 
No. of observations 384,047 (60,190) 655,714 (96,962) 
No. of unique reflections a 40,776 (6,194) 47,793 (7,417) 
Redundancya 9.4 (9.7)  
13.7 (13.1) 
 
Refinement   
Resolution (Å) 39.1 – 1.80  
No. of reflections 34,334  
No. of reflections test set 1,998  
Rwork / Rfree 16.0 / 20.0  
No. atoms (non-hydrogen) 2725  
    Protein 2561  
    Water 152  
    Ligand/Ions 12  
B-factors   
    Protein 31.7  
    Water 39.0  
RMSD   
    Bond lengths (Å)  0.010  
    Bond angles (°) 1.16  
Ramachandran plot   
    Favored (%) 98  
    Additionally allowed (%) 2.0  
    Outliers (%) 0.0  
TaHighest-resolution shell is shown in parentheses  
  
43 
Table 2.3 Table of genomes surveyed for TRC pathway proteins in figure 2.11 
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Materials and Methods 
Yeast two-hybrid 
The PJ69-4α strain was obtained from the Yeast Resource Center at the University of 
Washington. Bag6 fragments, A (1-225), B (226-399), C (400-659), D (660-950), E (951-
1126), Bag6EN (951-1011), Bag6ENLS (1012-1054), and Bag6EBAG (1055-1126) were 
cloned into pGAD-C1 vector. TRC35, TRC35-N (1-157), TRC35-C (158-327), and 
Ubl4A were cloned into pGBDU-C1 vector. Alanine mutants were made using site-
directed mutagenesis (Agilent Technologies). pGAD-C1 and pGBDU-C1 containing 
genes of interest were co-transformed into PJ69-4α using previously described methods 
(Gietz and Schiestl, 2007) andf then plated on SC-Ura-Leu and incubated at 30°C. The 
double transformants were then inoculated into 5 mL SC-Ura-Leu and grown over night 
in a shaking incubator at 200 rpm, 30 °C. From the cultures 2 × 107 cells were re-
inoculated into 5 mL total SC-Ura-Leu and grown in a shaker incubator for 6 hours. Cells 
were harvested by spinning at 3000 ×g at room temperature, washed twice with 5 mL 
sterile water. 1 × 107 cells were resuspended in 40 µL of sterile water. 4 µL of this 
resuspended sample were spot plated onto SC-Ura-Leu-Ade and grown for 72 hours at 
30°C. 
Cloning, expression and purification 
For crystallization, 54 residues from Bag6 (Q1054 to D1107) and the C-terminal 53 
residues from Ubl4A (P93 to K145) were co-expressed with pET33b plasmid with the N-
terminal 6x histidine tag on Ubl4A-C. To facilitate tobacco etch virus (TEV) cleavage of 
the histidine tag, three flexible residues, glycine, alanine, and serine, were inserted 
between the TEV cut site and P93 of Ubl4A using site-directed mutagenesis. The proteins 
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were expressed in E. coli NiCo21(DE3) (New England Biolabs) for 3 hours at 37°C after 
induction with 300 µM isopropyl-β-D-thiogalactopyranoside (Affymetrix). Cells were 
lysed using an S-4000 sonicator (Misonix) in 50 mM NaH2PO4, 200 mM NaCl, 20 mM 
imidazole supplemented with benzamidine, PMSF and 0.5% triton X-100. The complex 
was purified by nickel-nitrilotriacetic acid-agarose (Ni-NTA) affinity chromatography 
(Qiagen) then incubated overnight at room temperature with TEV protease in 20 mM 
NaH2PO4, 100 mM NaCl, 20 mM imidazole, and 10 mM β-mercaptoethanol followed by 
size-exclusion chromatography on Superdex 75 gel-filtration column in 10 mM Tris, 
50mM NaCl, pH 8.0 and concentrated to ~10 mg/ml. All truncations of Bag6 were 
purified using the protocol described above. C-terminal 53 residues from L1055 to 
D1107 of Bag6 were cloned for Bag6-BAG. Bag6-Ubl4A construct contained the C-
terminal 73 residues and full-length Ubl4A. C-terminal 175 residues from V951 to P1126 
were cloned in the Bag6 E fragment vector. Bag6-C81 contained the C-terminal 81 
residues from K1046 to P1126. 
All constructs were derived from human cDNA, specifically the major Bag6 isoform b 
(NP_542433.1). For crystallization, both Bag6 (1000 to 1054) and TRC35 (23 to 305) 
were inserted into the multiple cloning site of the pACYCDuet plasmid (Novagen) with 
an N-terminal hexahistidine tag on Bag6(1000-1054). The plasmid was transformed into 
E. coli NiCo21(DE3) (New England Biolabs). The plate was scraped to inoculate 12 × 2L 
baffled flasks containing 2xYT media then grown by shaking at 37°C in a shaking 
incubator (Multitron Standard Infors HT) at 250 rpm. Cell growth was monitored to an 
OD600 = 0.6 then protein expression was induced for 3 hours by the addition of 500 µM 
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isopropyl-β-D-thiogalactopyranoside (IPTG) (Affymetrix). Cells were harvested by 
centrifugation in a TLA 8.1 rotor at 4000 ×g for 20 minutes. The pellet was resuspended 
in 50 mM Mops pH 7.2, 300 mM K⦁glutamate, 5 mM MgOAc, 20 mM imidazole, 5 mM 
β-mercaptoethanol (1g cell / 10 mL lysis buffer) and supplemented with 0.1 mM PMSF 
and 1 mM benzamidine. Cells were lysed using an M-110L microfluidizer 
(Microfluidics) by two passes at approximately 17,500 psi. The lysate was clarified by 
centrifugation at 235,000 ×g in a Beckman Ti45 rotor for 30 minutes at 4°C. The clarified 
lysate was incubated for 1 hour with 3 mL of a 50% (vol/vol) slurry of nickel-
nitrilotriacetic acid (Ni-NTA) agarose (Qiagen) by rocking. The mix was poured into a 
gravity column then washed with 100 mL lysis buffer. The protein was eluted with 12 
mL elution buffer (20 mM Mops (pH 7.2), 150 mM K⦁glutamate, 300 mM Imidazole, 5 
mM β-mercaptoethanol). The eluent was mixed with ~0.5 mg of TEV protease in 
snakeskin dialysis tubing with 10 kDa molecular weight cutoff (Thermo Fisher 
Scientific) and dialyzed overnight at room temperature in (20 mM Mops (pH 7.2), 100 
mM K•glutamate, and 10 mM β-mercaptoethanol). Precipitate was removed by 
centrifugation with Beckman SX4750A rotor at 3000 ×g for 5 minutes at 4 °C and 
filtered with a 0.22 µm syringe filter. The sample was concentrated and loaded onto a 5 
mL UnoQ ion-exchange column (Biorad) then eluted with a 60 mL 20 mM Mops (pH 
7.2), 50 - 500 mM K•glutamate gradient, 5 mM β-mercaptoethanol. The fractions 
containing the protein (~5-23mL) were dialyzed in snakeskin dialysis bag in 20 mM 
Mops (pH 7.2), 50 mM K•glutamate, 5 mM β-mercaptoethanol for 2 hours at 4 °C. The 
sample was concentrated to 2 mL, filtered with a 0.22 µm syringe filter, and then further 
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purified by size-exclusion chromatography over a 120 mL Superdex 75 column (GE 
Healthcare) (20 mM Mops (pH 7.2), 50 mM K•glutamate, 5 mM β-mercaptoethanol). 
The fractions containing the heterodimer (61 mL – 72 mL) and monomeric Bag6 (77 mL 
– 82 mL) were pooled and concentrated to ~10 mg/mL using centrifugal filter units with 
10 kDa molecular weight cutoff (Merck Millipore). 
Circular dichroism 
Circular dichroism spectra were obtained using an Aviv 62A DS circular dichroism 
spectrometer. The ellipticity of 10 µM of Bag6-BAG, Ubl4A-C, or Bag6-Ubl4A 
suspended in 10 mM Tris, 50 mM NaCl, pH 8.0 was measured. 
Crystallization 
For the Bag6-Ubl4A dimer, crystallization screening was performed using the sitting 
drop vapor-diffusion method with commercially available screens (Hampton) and was set 
up by a Mosquito robot (TTP Labtech) and incubated at room temperature. The 
heterodimer crystallized after 4 days as rectangular prisms in 20% PEG-3350, 0.05 M 
Hepes, 1% tryptone (Hampton). They were soaked in 20% glycerol for 15 seconds and 
cryopreserved in liquid nitrogen. Iodide derivatives were generated by soaking crystals in 
40 µl mother liquor (20% PEG-3350, 0.05 M Hepes, 1% tryptone (Hampton)), 10 µl 
ethylene glycol, and 3 µl 6 M sodium iodide for 2 to 10 seconds prior to 
cryopreservation. 
For the Bag6-TR35 dimer, crystallization screening was performed using the sitting drop 
vapor-diffusion method with the commercially available PEG Ion screen (Hampton 
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Research) and MRC 2 Well Crystallization plate (Hampton Research). Initial screening 
was performed by a Mosquito robot (TTP Labtech) with 100nL:100nL drops 
(protein:well solution) and 50 µL wells. No refinement was necessary. Crystals grew to 
full-size after 5 days as rectangular prisms in 20% PEG-3350 (wt/vol), 0.2 M DL-malic 
acid (pH 7.0). For cryo-protection, crystals were transferred into 100uL of well solution 
with 20% (vol/vol) glycerol for 15 seconds and then frozen in liquid nitrogen. Rubidium 
derivatives were generated by transferring crystals into 40 µl well solution plus 350 mM 
rubidium iodide for 2 to 10 seconds prior to cryopreservation with glycerol. 
Data collection, structure solution and refinement 
For the Bag6-Ubl4A structure, x-ray diffraction data were collected on beam line 8.2.1 at 
the Advanced Light Source (ALS) at Lawrence Berkeley National Laboratory. A 
complete dataset was collected from a single crystal to 2.1 Å resolution. Data were 
integrated, scaled, and merged using MOSFLM (Battye et al., 2011) and SCALA 
(Collaborative Computational Project, 1994; Winn et al., 2011). Phases were determined 
by single-wavelength anomalous dispersion data merged from three iodide derivative 
crystals, which diffracted to 3.5 Å. The model was refined using COOT (Emsley et al., 
2010) and PHENIX (Adams et al., 2010) . Statistics are provided in Table 1. 
For the Bag6-TRC35 dimer, x-ray diffraction data were collected on beam line BL12-2 at 
the Stanford Synchrotron Radiation Laboratory (SSRL). A complete native dataset was 
collected from a single crystal to 1.8 Å resolution and a single rubidium derivative crystal 
dataset was collected from a single crystal to 2.0 Å with a Dectris Pilatus 6M detector. 
Data were integrated, scaled, and merged using XDS (Kabsch, 2010) and SCALA 
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(Collaborative Computational Project, 1994; Winn et al., 2011). Phases were determined 
by molecular replacement single-wavelength anomalous dispersion (MRSAD) using 
SHARP (Bricogne et al., 2003) and PHASER-MR (McCoy et al., 2007) on PHENIX 
(Adams et al., 2010). The initial structure was built by PHASER as implemented by 
PHENIX (Adams et al., 2010). The model was further built and refined against the native 
dataset over several rounds using COOT (Emsley et al., 2010) and PHENIX (Adams et 
al., 2010). Statistics are provided in Table 2. 
Phylogenetic Tree of GET/TRC Components 
The phylogenetic tree was modified from the maximum likelihood phylogenetic tree of 
eukaryotes by Eme et al (Eme et al., 2014). The MEME suite (Bailey et al., 2009) was 
used to determine the presence or absence of the GET/TRC components in the genomes 
presented in the tree. The MEME motif discovery tool was used to make motifs for 
Ubl4A, Get5, Get4/TRC35, and Sgt2, SGTA, and Bag6. The motifs were then used to 
search the genomes using the motif-scanning tool MAST (Bailey and Elkan, 1994). 
Identified proteins were confirmed using BLAST (Altschul et al., 1990) and the 
corresponding reference ID is provided on table 3. 
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BIOCHEMICAL CHARACTERIZATION OF THE BAG DOMAIN 
AND THE MINIMAL TA TARGETING MODULE 
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Abstract 
The metazoan protein BCL2-associated athanogene cochaperone 6 (Bag6) forms a hetero-
trimeric complex with ubiquitin-like 4A (Ubl4A) and transmembrane domain recognition 
complex 35 (TRC35). This Bag6 complex is involved in tail-anchored protein targeting and 
various protein quality control pathways in the cytosol as well as regulating acetylation and 
histone methylation in the nucleus. Crystal structure of the Bag6 BAG domain revealed 
that it does not fold into a canonical BAG domain fold. In this study, we biochemically 
demonstrate that Bag6-BAG domain does not behave like a canonical BAG domain, 
establishing it as a “mock” BAG domain. Furthermore, we show that C-terminal 125 
residues of Bag6, which can form a stable complex with TRC35 and Ubl4A, are sufficient 
for TA targeting.   
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Introduction 
BCL2-associated athanogene cochaperone 6 (Bag6, also known as “BAT3” or “Scythe”) 
is a metazoan protein that is involved in membrane protein targeting and quality control 
in the cytosol. Biochemical (Mariappan et al., 2011; Stefanovic and Hegde, 2007; Wang 
et al., 2011b) and structural studies (Mock et al., 2015) have demonstrated that Bag6 
forms a stable heterotrimer with transmembrane domain recognition complex 35 
(TRC35) and ubiquitin-like 4A (Ubl4A).  
Crystal structures of the Bag6-Ubl4A and Bag6-TRC35 complexes revealed that the 
Bag6 BAG domain, previously designated based sequence homology and biochemical 
characterization (Thress et al., 2001), does not resemble the canonical three helix bundle 
conformation of other BAG domains (Fig. 2.5). Furthermore, despite organizational 
changes from the heterotetrameric fungal complex to the heterotrimeric metazoan 
complex, all the functional domains required for TA targeting are structurally conserved. 
The fungal heterotetrameric Get4-5 sorting complex binds Sgt2 via the UBL domain of 
Get5 (Chartron et al., 2012b; Xu et al., 2012). The N-terminal domain of Get4 binds and 
regulates the ATPase activity of Get3 (Chartron et al., 2010; Gristick et al., 2014; Rome 
et al., 2013). Structurally, the UBL domain of Get5 and the N-terminal domain of Get4 
have both been conserved in the metazoan homologues, Ubl4A and TRC35, respectively. 
This suggests that the minimal Bag6 complex structurally characterized in chapter 1 is 
functionally equivalent to the fungal Get4-5 complex.  
This chapter seeks to functionally verify structural observations using biochemical 
methods. In vitro Hsc70-mediated refolding assay was used to confirm that the Bag6 
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BAG domain does not behave like a canonical BAG domain, which binds and inhibits 
Hsc70 in vitro. Furthermore, the minimal Bag6-TRC35-Ubl4A complex identified and 
structurally characterized in chapter 2 facilitates TA protein transfer from SGTA to 
TRC40 in vitro. These findings establish the minimal Bag6 complex identified in this 
study as a TA targeting module.  
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Results 
Functional characterization of the Bag6-BAG domain 
Previous results have shown that the ability of Bag6 to inhibit Hsc70 refolding of 
substrates in vitro is dependent on the presence of the C-terminal 81 residues (Bag6-
C81), which include the BAG domain (Thress et al., 2001). This was suggested to be 
equivalent to results for the Bag1 BAG domain, a demonstrated nucleotide exchange 
factor for Hsc70 (Sondermann et al., 2001). If true, Bag6-BAG should inhibit Hsc70-
mediated protein folding. To assay this, denatured β-galactosidase was folded in vitro in 
the presence of human Hsc70 and Hdj1, as done previously (Freeman and Morimoto, 
1996; Thress et al., 2001). Folding was measured as a percent of β-galactosidase activity 
recovered after the folding reaction was quenched. With both Hsc70 and Hdj1 present a 
maximal refolded activity of ~35% was recovered after 180 min (Fig. 3.1, brown line) 
while no refolding was seen when only BSA was added (black line). The addition of 
human Bag1-BAG to Hsc70 and Hdj1 completely inhibited the ability of Hsc70 to fold 
the protein (purple line) consistent with previous results (Takayama et al., 1997). 
Conversely, the addition of Bag6-BAG had no effect on refolding by Hsc70 (orange solid 
line). 
The inconsistency with previous results might be explained by co-purification of 
endogenous Bag6 binding partners. In the earlier study, an affinity-tagged full-length 
human Bag6 and C-terminal 81 residues of Bag6 (Bag6-C81) were expressed and 
purified from insect cells over a single affinity resin (Thress et al., 2001). As the proteins 
are well conserved, it is reasonable to assume that endogenous insect Ubl4A could be a 
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contaminant and may contribute to the inhibition. The introduction of the Bag6-
BAG/Ubl4A complex to the reaction had no effect on folding (blue line). SGTA, a co-
chaperone, has recently been shown to form a specific complex with Ubl4A (Xu et al., 
2013) and may also have been in the endogenously purified sample. SGTA had no 
significant effect on activity (Fig. 3.2) with or without the other factors (Fig. 3.1A, 
dashed lines). Bag6-C81, which was required for inhibition in the previous study, is 
slightly larger than the BAG domain defined here (Fig. 2.1A). However, using this larger 
fragment also had no effect on folding (Fig. 3.2). Together, these results suggest that 
although the C-terminal 81 residues of Bag6 are required for its chaperoning activity, it 
does not act as a bona fide BAG domain to cooperate with Hsc70. 
This conclusion was further supported by binding assays. A 6xHis-tagged Hsc70-NBD 
(Nucleotide Binding Domain), the expected binding site for Bag proteins, was incubated 
with purified Bag6-C81, Bag6-BAG, Bag6-BAG/Ubl4A, or Bag1-BAG. After 
incubation, Hsc70-NBD was captured on Ni-NTA beads along with any associated 
protein. As expected, Hsc70-NBD could capture the Bag1-BAG (Fig. 3.3). On the other 
hand, Hsc70-NBD was unable to capture any of the Bag6 C-terminal fragments at levels 
above background. Thus, one would conclude that Bag6-BAG is unlike canonical BAG 
domains in its ability to interact with Hsc70 in vitro. 
While the evidence makes it clear that the Bag6 BAG domain does not interact with 
Hsc70 in isolation, the role of other unknown factors could not be ruled out. For instance, 
SGTA could mediate the interaction between Bag6-BAG and Hsp70 as it binds Hsp70 
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via its tetratricopeptide repeat (TPR) domain and Ubl4A via its N-terminus (Chartron et 
al., 2012b). To address the possibility of accessory factors, tagged variants of BAG 
domains were incubated with 293T whole cell lysate (Fig. 3.1B). The positive control 
Bag1-BAG again could capture a significant amount of Hsc70. A complex with Bag6-
BAG and Ubl4A, either the crystallized fragment or the full-length, was unable to capture 
Hsc70. 
These results contrast with previous experimental results in which Bag6 inhibition of 
Hsc70 was dependent on the presence of the BAG domain (Thress et al., 2001). This 
could not rule out the possibility of binding Hsc70 in the context of the full-length Bag6. 
To test this, 293T cells were transfected with either FLAG-Bag6 or FLAG-Bag6ΔC81 
and captured with anti-FLAG resin. Proteins bound to the beads were blotted with both 
Bag6 (green) and Hsc70 (red) antibodies. Full-length Bag6 captured a small amount of 
Hsc70 over background; however, the lack of the previously annotated BAG domain, 
Bag6ΔC81, had no effect on the amount of captured Hsc70 (Fig. 3.1C). Combined, these 
results suggest that Bag6-BAG, both structurally and biochemically, is not a true BAG 
domain. 
Expression and purification of Bag6min complex 
The next goal was to purify the hetero-trimeric complex. Both full-length Bag6 and 
TRC35 were recalcitrant to recombinant expression in E. coli. For TRC35, expression 
required removal of residues at the N- and C-terminus that are not conserved, TRC35(23-
305). This truncated TRC35 behaved as wild-type by yeast 2-hybrid with Bag6E (Fig. 
3.4A). Additionally, based on the interaction results, a minimal Bag6 fragment (Bag6min) 
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was constructed, residues 1001 to 1126, that removed the N-terminal 50 residues of 
Bag6E. Co-expressing Bag6min, TRC35(23-305) and Ubl4A resulted in a stable complex 
that could be purified (Fig. 3.4).  
The Bag6min complex is an independent module that facilitates TA handoff 
The fungal Get4-5 complex binds ATP bound Get3 and inhibits its ATPase activity 
priming Get3 for TA substrate capture from Sgt2 (Gristick et al., 2014; Rome et al., 2014). 
One would expect that the trimeric Bag6 complex, which contains the mammalian Get4-5 
orthologues, regulates TRC40 in a similar manner. To test this, an in vitro assay was 
developed to probe the role of the Bag6min complex in TA handoff from SGTA to TRC40 
using recombinantly purified proteins (scheme in Fig. 3.5A). When co-expressed, fungal 
Sgt2 binds GET dependent TA substrates and this complex can be purified (Wang et al., 
2010). Here, histidine-tagged SGTA (hSGTA) was co-expressed in E. coli with the yeast 
TA protein Sbh1 that contained an N-terminal maltose-binding protein (MBP•Sbh1) 
resulting, after a two-step purification, in a stable hSGTA/MBP•Sbh1 complex (Fig. 3.4B). 
The final component, TRC40, was generated as a N-terminal glutathione-S-transferase tag 
(GST•TRC40) (Fig. 3.4B), as done previously (Vilardi et al., 2011; Yamamoto and 
Sakisaka, 2012). Transfer was initiated by incubation of hSGTA/MBP⦁Sbh1 with either 
GST•TRC40 alone or with the Bag6min complex (Fig. 3.5A). The samples were then 
precipitated with anti-GST resin, washed in two steps in the absence of ATP, and then 
probed after Western blotting with both MBP and GST antibodies.  
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GST•TRC40 was able to capture some TA from SGTA alone as seen before for the yeast 
system (Wang et al., 2010) (Fig. 3.6). The additional presence of the Bag6min complex 
resulted in an ATP-dependent increase in TA transfer to TRC40 (compare lanes 4 & 6).  
This was not a result of a bridged capture of TRC40 pulling down TA still bound to SGTA. 
The interaction between SGTA and Ubl4A is predicted to have very fast off-rates (Chartron 
et al., 2012b) and SGTA would be rapidly removed during the wash steps. Moreover, 
capture of TA by TRC40 was insensitive to increasing salt concentration (Fig. 3.6) despite 
the SGTA/Ubl4A and TRC35/TRC40 interactions being dominated by electrostatics, the 
latter also requiring ATP (Chartron et al., 2012b; Gristick et al., 2014). The Bag6min 
fragment used in the study does not contain the Bag6 substrate-binding domain (Leznicki et 
al., 2013); therefore, the Bag6 complex can promote substrate hand-off from SGTA to 
TRC40 without Bag6 directly engaging the substrate. 
SGTA binds the Bag6 complex via the UBL domain of Ubl4A; consequently, the Bag6 
dependent hand-off should require this interaction (Chartron et al., 2012b; Xu et al., 2012). 
To address this, the mutants hSGTA(C38A) and Ubl4A(L43A) were generated where the 
equivalent mutations in yeast were previously shown to disrupt the homologous interaction 
(Chartron et al., 2012b). As expected, each resulted in a similar loss of substrate hand-off 
relative to wild type (Figs. 3.5B and 3.7C). This highlights the importance of this 
interaction for the bridging by Bag6 during TA transfer. 
In yeast, Get4-5 binding regulates Get3 ATPase activity and TA targeting (Rome et al., 
2013). Therefore, in addition to the bridging role of the Bag6 complex, it is critical to test if 
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this larger complex plays a regulatory role in TA targeting. The crystal structure of yeast 
Get4 bound to Get3 highlighted a regulatory interface separate from the binding interface 
(Gristick et al., 2014). When mutated, residues on either side of this regulatory interface 
(the charge swaps K69D on Get3 and D74K on Get4) each resulted in a loss of ATPase 
inhibition, reduction of TA insertion into microsomes, and a loss of fitness in vivo, despite 
maintaining a stable complex in vitro (Gristick et al., 2014). Combining the charge swap 
mutants restored the Get4 regulatory activity (Gristick et al., 2014). For TRC40, the 
corresponding regulatory mutation, K86D, resulted in a reduction of the Bag6 complex 
facilitated hand-off (Fig. 3.5C, compare lanes 4 & 8 and Fig. 3.7D). Similarly, the 
corresponding regulatory mutation in TRC35, D84K, resulted in a reduction of facilitated 
hand-off (compare lanes 4 & 5 and Fig. 3.7D). Excitingly, as seen for the yeast system 
(Gristick et al., 2014), the combination of these two charge swap mutants resulted in a 
rescue of the facilitated hand-off (lane 9 and Fig. 3.7D). These results highlight that this 
minimal Bag6 complex acts as an independent TA targeting module and performs a similar 
regulatory role to the fungal Get4-5 complex despite the different architectures. 
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Discussion 
Our structural characterization of the mammalian TA sorting complex in chapter 1 
established Bag6 as a scaffolding factor that forms a stable complex with TRC35 and 
Ubl4A. The structure of the putative BAG domain, however, did not resemble published 
structures of canonical BAG domains. Meanwhile, although the introduction of Bag6 alters 
the overall molecular architecture in mammals relative to that of yeast, all the functional 
elements required to bind and regulate relevant TA components, Sgt2/SGTA and 
Get3/TRC40, were conserved in the Bag6 complex. In this chapter, we biochemically 
confirm that Bag6 BAG domain is not a BAG domain. Furthermore, we define and 
characterize in vitro a minimal Bag6 TA targeting module that is sufficient for TA handoff. 
The demonstrated inability of Bag6-BAG to influence Hsc70 activity is unsurprising if 
one considers sequence and structural comparisons with canonical BAG domains. This 
result brings into question the reported inhibition of Hsp70-mediated β-galactosidase 
refolding by Bag6 (Thress et al., 2001). A possible explanation is the holdase activity of 
Bag6. Bag6 prevents the aggregation of unfolded luciferase by forming a stable 
interaction with the exposed hydrophobic core, preventing Hsp70-mediated refolding 
(Wang et al., 2011b). Similar Bag6 holdase activity may have prevented refolding of β-
galactosidase. Deletion of the 81 C-terminal residues may disrupt this holdase through an 
unknown mechanism, possibly by occluding the binding site on the truncated Bag6. The 
observed Hsp70 inhibition by Bag6, therefore, would be a result of sequestration of the 
unfolded substrate by Bag6 via its hydrophobic substrate-binding region, which also 
could be recognized by Hsp70, resulting in the interaction between Bag6 and Hsp70. 
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While full-length Scythe and Bag6 inhibit reaper and ricin-triggered apoptosis, excess 
ScytheC312 (Thress et al., 1998) or the C-terminal 131 residues (Wu et al., 2004) of 
Bag6 can induce apoptotic events. As the C-terminal fragment would be consistent with 
the Bag6min complex defined here, excess Bag6 C-terminus would disconnect the triaging 
and holdase/degradation roles of the complex. The apoptosis connection could then be 
linked to tail-anchor targeting. Overexpression of Bag6 in HeLa cells exposed to ricin, an 
apoptosis inducer, leads to an increase in endogenous Bcl-2 protein levels, whereas Bag6 
knockdown causes down-regulation of Bcl-2 proteins (Wu et al., 2004). Several proteins 
that belong to the Bcl-2 family are tail-anchored, including Bcl-2, MCL1, BAX, and 
BOK, and reside both at the ER and the mitochondria (Echeverry et al., 2013; Strasser, 
2005; Szegezdi et al., 2009). The Bag6 complex would then play an important role in 
regulating the localization and turnover of these Bcl-2 proteins, which could be altered by 
Bag6 cleavage. 
The results presented in this chapter establish the C-terminal domain of Bag6 as an 
independent TA targeting module of Bag6. The N-terminal UBL domain of Bag6 
connects the proteasome, where it interacts with RP non-ATPase 10c (Kikukawa et al., 
2005), with components of quality control pathways, where it interacts with RNF126, 
gp78 and ubiquitin regulatory X domain-containing protein 8 (Rodrigo-Brenni et al., 
2014; Wang et al., 2011b; Xu et al., 2013). Downstream of this connection, the proline-
rich domain has been implicated as the holdase domain binding to exposed hydrophobic 
regions and polyubiquitylated defective ribosomal products (Leznicki et al., 2013; 
Minami et al., 2010; Wang et al., 2011b). Bag6 then acts as a scaffolding protein, 
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simultaneously binding ubiquitylation machinery, the proteasome, TA-targeting factors, 
and proteins to be triaged. Recent biochemical characterization of the triaging process 
revealed that TA substrate that is not handed off to TRC40 within ~3 cycles is rerouted to 
the degradation pathway by Bag6 (Shao et al., 2017). The molecular details of how its 
decision-making process relates to its other functions in apoptosis, gene regulation, and 
immunoregulation are important questions for future studies.  
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Figures 
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Figure 3.1. Bag6-BAG is not a canonical BAG domain 
(A) Hsc70-mediated refolding of β-galactosidase in the presence of Bag1-BAG (purple), 
Bag6-BAG (orange solid), Bag6EBAG/Ubl4A (blue solid), SGTA & Bag6-BAG (orange 
dashed), SGTA & Bag6EBAG/Ubl4A (blue dashed) or BSA (black) as a negative control. 
(B) Affinity tagged Bag6-BAG, Bag6EBAG/Ubl4A, Bag6-BAG/Ubl4A-C or Bag1-BAG 
was loaded onto cobalt resin beads and incubated with 293T whole cell lysate. Eluted 
samples were immunoblotted with Hsc70 antibody (top panel) and Ponceau stained 
(bottom panel). (C) FLAG-Bag6 or FLAG-Bag6ΔC81 was overexpressed in 293T cells 
and anti-FLAG resin was used to capture them with bound factors. Bag6 antibody on the 
blot is detected in green, and Hsp70 antibody in red.  
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Figure 3.2. Individual results for various in vitro refolding assays 
β-Galactosidase refolding assays in the presence of Hsc70, Hdj1 and/or other factors 
(labeled). Colors are based on Figure 3.1 except for assays containing Bag6-C81 that are in 
cyan. Error bars are from three independent experiments.  
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Figure 3.3. Bag6-BAG does not bind Hsc70 nucleotide binding domain (NBD) 
In vitro capture by 6xHis-Hsc70-NBD of Bag6-BAG, Bag6-C81, Bag6EBAG/Ubl4A, or 
Bag1-BAG. Protein was pulled down (PD) with Ni-NTA after incubation with 6xHis-
Hsc70-NBD. Four percent of total loaded protein is shown as a loading control (LC), and 
each protein was incubated alone with Ni-NTA (Ni) to assess background binding.   
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Figure 3.4. Purification of recombinant proteins used in TA transfer assay 
(A) Two-hybrid using full-length TRC35 and TRC35(23-305) with Bag6E fragment. Both 
TRC35 constructs display strong two-hybrid interactions. (B) Representative Coomassie 
stained 12% SDS-PAGE gel of purified hSGTA/MBP⦁Sbh1, Bag6min Complex, and 
GST⦁TRC40. 
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Figure 3.5. The Bag6min complex facilitates TA transfer from SGTA to TRC40 
(A) The in vitro TA handoff reaction scheme. Recombinantly purified hSGTA-MBP⦁Sbh1 
complex was incubated with GST⦁TRC40 and indicated recombinant proteins. After 
incubation on ice for 10 minutes, GST⦁TRC40 and bound substrate were precipitated with 
anti-GST resin followed by three wash steps and Western blotting. (B) Mutants affecting 
SGTA binding to the Bag6min complex reduce TA transfer to TRC40. GST⦁TRC40 was 
captured on anti-GST resin after incubation in the presence of ATP with SGTA/MBP-Sbh1 
or SGTA(C38A)/MBP⦁Sbh1 alone or with the Bag6min or Bag6min(Ubl4A(L43A)) 
complex. Eluted samples were immunoblotted with anti-GST (red) and anti-MBP antibody 
(green) then quantified by Odyssey Infrared Imaging System analysis software. Relative 
values of captured Sbh1 underneath each lane with the experiment containing all wild-type 
components as the reference. Sbh1 fluorescence values were normalized for each trial 
based GST⦁TRC40 captured in each lane. Values are averages of six independent 
experiments. Standard deviations are included in figure 3.7. The 5% rxn lane corresponds, 
in all cases, to loading 5µL of the wild-type reaction prior to capture. (C) Regulatory 
mutants GST⦁TRC40(K86D) and TRC35(D84K)Bag6min complex were incubated with 
indicated recombinant proteins and ATP then captured on anti-GST resin and analyzed as 
in B. 
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Figure 3.6. The Bag6min complex facilitates TA transfer from SGTA to TRC40 in an 
ATP dependent manner  
Nucleotide-dependent TA handoff facilitated by Bag6min complex. GST⦁TRC40 was 
captured on anti-GST resin after incubation with SGTA-MBP⦁Sbh1 and Bag6min complex 
with or without ATP. Eluted samples were immunoblotted with anti-GST (red) and anti-
MBP antibody (green) then quantified by Odyssey Infrared Imaging System analysis 
software and the Sbh1 values were normalized based on total GST⦁TRC40 captured. 
MBP⦁Sbh1 signal from WT experiment was designated 1, and the rest represented as a 
fraction of the WT value. Values are the average of four independent experiments. 
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Figure 3.7. TA handoff from SGTA to TRC40 
(A) Average values of nucleotide-dependent TA handoff from SGTA to TRC40 facilitated 
by Bag6min complex. Error bars are from four independent experiments. (B) Average 
values of TA handoff from SGTA to TRC40 facilitated by Bag6min complex in the presence 
of ATP washed with buffers with varying salt concentrations. Error bars are from three 
independent experiments. Fluorescence values are represented as a percentage of WT 
handoff as measured by MBP fluorescence. (C) Average values of TA handoff by binding 
mutants hSGTA(C38A)/MBP⦁Sbh1 and Bag6min(Ubl4A(L43A)) complex as compared to 
WT. Error bars are from six independent experiments. (D) Average values of TA handoff 
of regulatory mutants GST⦁TRC40(K86D) and Bag6min(TRC35(D84K)) complex as 
compared to WT. Error bars are from four independent experiments. 
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Materials and Methods 
Cloning, Expression, and Purification. cDNA of human Hsc70, Hdj1, and Hsc70-NBD 
(P5 to S381) were subcloned into pET33b vector, expressed, and purified similar to 
previously described methods with some modifications (Chartron et al., 2012b). Full-
length Hsc70 and Hsc70-NBD were purified over a UnoQ column (Biorad) (50 mM 
Hepes, 50 - 500 mM KCl gradient, pH 8.0, 5 mM β-mercaptoethanol). Hdj1 was purified 
over a UnoS column (50 mM Hepes, 20 mM KCl 500 mM KCl, pH 7.0, β-
mercaptoethanol). The plasmid vectors containing the cDNA of the chaperone proteins 
were obtained from the Morimoto group at Northwestern University (Freeman and 
Morimoto, 1996). 
cDNA of human TRC40 was subcloned into pGEX-6P-1 vector and expressed in 
NiCo21(DE3) cells. Cells were lysed using a M-110L Microfluidizer Processor 
(Microfluidics) in 50 mM NaH2PO4 and 400 mM NaCl supplemented with benzamidine, 
PMSF, and 5mM β-mercaptoethanol. The protein was purified in a single step 
Glutathione SuperFlow resin affinity chromatography (Clontech). cDNA of human 
SGTA was subcloned into pET33b vector, and co-expressed with MBP-Sbh1 in 
pACYCDuet vector in NiCo21(DE3) cells and lysed using a M-110L Microfluidizer 
Processor (Microfluidics) in 50 mM NaH2PO4, 150 mM NaCl, 20 mM imidazole 
supplemented with benzamidine, PMSF, and 5mM β-mercaptoethanol. The complex was 
purified in two steps using Ni-NTA resin (Qiagen) and amylose resin (NEB). Human 
TRC35(23-305) was subcloned from TRC35 cDNA into pACYCDuet vector in the first 
multiple cloning site (MCS) with N-terminal 6x histidine tag and a TEV protease cut site. 
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In the second MCS, cDNA of untagged human Ubl4A was subcloned. TRC35 and was 
co-expressed with untagged Bag6(1001-1126) in pET33b in NiCo21(DE3). The complex 
was purified by Ni-NTA affinity chromatography (Qiagen). Contaminants were further 
removed using chitin affinity chromatography (NEB). TRC40(K86D), TRC35(D84K), 
SGTA(C38A), and Ubl4A(L43A) mutants were generated using site-directed 
mutagenesis (Agilent Technologies). 
Hsc70 refolding assay. The Hsc70 mediated β-galactosidase refolding assay was carried 
out as previously reported with modifications. Stock solution of β-galactosidase at 10 
mg/ml was prepared by dissolving the enzyme (Sigma-Aldrich) in 50 mM Tris-HCl, 10 
mM MgCl2, 5mM β-mercaptoethanol (pH 7.3). For experiments, the stock enzyme was 
1:10 diluted in 1 M glycylglycine (pH 7.4). 5 µl of this was diluted into 95 µl of 
unfolding buffer (25 mM Hepes, 5 mM MgCl2, 50 mM KCl, 5 mM β-mercaptoethanol, 6 
M guanidine-HCl, pH 7.4), and 5 µl was diluted into 95 µl 1 M glycylglycine pH 7.4 for 
the control. Final β-galactosidase concentration was 3.4 nM. The two samples were 
incubated at 30°C for 30 minutes. 
Folding reactions were performed in refolding buffer (1.6 µM Hsc70 and 3.2 µM Hdj1 
suspended in 25 mM Hepes, 5 mM MgCl2, 50 mM KCl, 2 mM ATP, 10 mM DTT, pH 
7.4). Varying concentrations of Bag6 constructs were tested for their effect on Hsc70 
folding activity. After a 30 minute incubation at 30°C, 1 µl of denatured enzyme was 
added to 124 µl of each refolding reaction tube and incubated at 37 °C. In regular time 
intervals, 10 µl of each folding reaction was added to 10 µl of 0.8 mg/ml ONPG (ortho-
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nitrophenyl-β-galactoside) and incubated at 37°C for 15 minutes. The reaction was 
stopped by the addition of 80 µl 0.5 M sodium carbonate. β-galactosidase activity was 
measured as a rate of conversion of ONPG by absorbance at 413 nm. 
Hsc70 capture assay 
500 pmol of Hsc70-NBD with N-terminal 6x histidine tag was incubated with 2 nmol of 
untagged Bag6-BAG, Bag6-C81, Bag6EBAG/Ubl4A, and Bag1-BAG in total 100 µl of 
binding buffer (20 mM Hepes, 100 mM KCl, 20 mM imidazole, and 5 mM β-
mercaptoethanol) for 1 hour at room temperature. The samples were then added to 15 µl 
of Ni-NTA beads (Qiagen). The beads were washed twice with 100 µl binding buffer. 
Bound proteins were eluted with 15 µl of 20 mM Hepes, 100 mM KCl, 300 mM 
imidazole, and 5 mM β-mercaptoethanol then run on to 4-20% gradient SDS-PAGE gel 
(Biorad). 4% of total sample was run as loading control. 
For capture assays from 293T whole cell lysate, cells from 10cm dish (90% confluent) 
were lysed in 1.5 ml NP40 lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM 
MgCl2, 0.5% NP40, 2 mM β-mercaptoethanol, protease inhibitor cocktail). Cell extracts 
were subject to centrifugation at 20,000 ×g for 5 min to remove insoluble materials. The 
soluble fractions were pre-treated with 180 ml HisPurTM Coblat resin (Thermo) and then 
incubated with 30 ml HisPurTM Coblat resin immobilized with His-tagged Bga6-
fragments as indicated in the figure at 4 degree for 1 hour. The resins were quickly 
washed twice with 400 ml a wash buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM 
MgCl2), 0.1% NP40, and 2 mM β-mercaptoethanol. The proteins bound to the resin were 
eluted with 60 ml SDS-PAGE loading buffer and denatured by heating at 65 °C for 10 
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minutes. The samples were analyzed by SDS-PAGE. Proteins were detected by either 
Ponceau staining and immunoblotting. 
To examine in vivo interaction of Bag6 and Hsp70, cells grown in a 6 well plate were 
transfected with plasmids expressing FLAG-tagged wild type Bag6 or a mutant Bag6 
lacking the C-terminal 81 amino acids using TransIT 293 (Mirus). Cells were lysed in the 
NP40 lysis buffer 24 hours post transfection. Bag6 was pulled down from the lysate by 
FLAG M2 beads (Sigma-Aldrich). The precipitated material was analyzed by 
immunoblotting. 
In vitro TA handoff assay 
0.625 pmol of hSGTA/MBP⦁Sbh1 or hSGTA(C38A)/MBP⦁Sbh1 was incubated with 
0.04 µg/µL (6.25 pmol) GST⦁TRC40 or GST⦁TRC40(K86D) with or without 0.008 
µg/µL of Bag6min, Bag6min(D84K), or Bag6min(L43A) complex in 100 µL of incubation 
buffer (50 mM Hepes (pH 7.5), 4 mM Mg(OAc)2, 150 mM KOAc, 10% glycerol, and 1 
mM DTT) on ice for 10 minutes. After 10 minutes, 10 µL of MagnetGST resin 
(Promega) was added to each reaction and incubated at room temperature for 15 minutes 
to pull down GST⦁TRC40 and bound factors. The resin was washed three times with 500 
µL of incubation buffer and eluted with 20 µL of 20 mM Tris, 300 mM NaCl, and 33 
mM L-Glutathione pH 7.4. The precipitated material was analyzed by immunoblotting. 
For the wild-type capture experiment, approximately 12 ± 5.2% of TRC40 and 4.1 ± 
1.6% of Sbh1 were eluted from the beads. Assuming one TA per TRC40 dimer, one 
would expect ~6% of the TA to be captured assuming 100% transfer; therefore, our yield 
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is reasonable and differences could be attributed to a variety of factors such as 
differences in stoichiometry assumptions or affinities of the various TRC40 complexes. 
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C h a p t e r  4  
BIOCHEMICAL AND CELL BIOLOGICAL INVESTIGATION OF 
THE MECHANISM FOR NUCLEO-CYTOPLASMIC 
DISTRIBUTION OF BAG6 BY TRC35 
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Abstract 
The metazoan protein BCL-2 associated athanogene cochaperone 6 (Bag6) acts as a 
central hub for several essential cellular processes, including immunoregulation, gene 
regulation, autophagy, apoptosis, and proteostasis. These roles are in both the nucleus and 
the cytosol, but the mechanism by which Bag6 trafficking is regulated remains elusive. 
Here we present biochemical and cell biological characterization of the cytoplasmic 
retention factor of Bag6, transmembrane domain recognition complex 35 (TRC35). 
Disrupting the interface between Bag6 and TRC35 results in nuclear localization of 
Bag6. TRC35 binds Bag6 with higher affinity than karyopherins. Free TRC35 that cannot 
bind Bag6 at its native binding site is ubiquitylated and degraded. Combined, these 
results suggest a mechanism for regulation of the nucleo-cytoplasmic distribution of 
Bag6. 
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Introduction 
The metazoan protein Bag6 is a multidomain protein implicated in various essential 
cellular processes. Recent efforts have elucidated its extensive cytosolic role as a protein 
targeting and quality control triaging factor (Mock et al., 2015; Rodrigo-Brenni et al., 
2014; Shao et al., 2017; Wang et al., 2011b). It is well known, however, that Bag6 can 
localize to the nucleus via its nuclear localization sequence (Manchen and Hubberstey, 
2001), which has been assumed to be a bipartite nuclear localization sequence. 
Several studies have investigated nuclear roles of Bag6. First, Bag6 modulates histone 
methylation. In U2OS cells, Bag6 constitutively co-localizes in the nucleus with DOT1 
Like histone methyltransferase (DOT1L) (Wakeman et al., 2012), a methyltransferase 
that methylates histone 3 at lysine 79 (H3K79). siRNA-mediated knockdown of Bag6 
results in reduced DOT1L-dependent H3K79 methylation in cells treated with ionizing 
radiation (Wakeman et al., 2012). In HCT116 cells, Bag6 interacts with Brother Of the 
Regulator of Imprinted Sites (BORIS), a DNA-binding protein that localizes to the 
promoter regions of myc and BRCA1 (Nguyen et al., 2008). Bag6 binding facilitates 
BORIS-mediated histone 3 lysine 4 (H3K4) dimethylation (Nguyen et al., 2008).  
Bag6 is also implicated in regulating the acetyltransferase p300. Bag6 promotes the 
interaction between p300 and p53 (Sasaki et al., 2007), which is crucial for p300-
mediated acetylation of p53 in the nucleus. siRNA-mediated knockdown of Bag6 results 
in reduced p300-mediated acetylation of p53, which cannot be rescued by expressing 
Bag6ΔNLS (Sasaki et al., 2007). Another study showed that Bag6 promotes p300-
mediated p53 acetylation but inhibits p300-mediated acetylation of ATG7 (Sebti et al., 
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2014b). These cells also cannot be rescued by expressing Bag6 ΔNLS mutant (Sebti et 
al., 2014b). Notably, in Bag6-/- mouse embryonic fibroblasts, Bag6 is a nuclear shuttling 
factor of p300 (Sebti et al., 2014a, b).  
Other examples include cell cycle dependent (Yong and Wang, 2012) and ionizing 
radiation-induced nuclear localization of Bag6 (Krenciute et al., 2013).  
While it is clear that some endogenous Bag6 is translocated into to the nucleus, our 
understanding of the molecular mechanism by which Bag6 distribution is modulated 
between the nucleus and the cytoplasm is lacking. Importantly, many localization studies 
did not consider the molecular characterization of the Bag6 complex that includes 
TRC35, which binds and retains Bag6 in the cytosol (Mock et al., 2015; Wang et al., 
2011b). There is strong evidence that Bag6, TRC35 and Ubl4A exist in a trimeric 
complex in the cytoplasm (Hessa et al., 2011; Liu et al., 2014; Mariappan et al., 2010; 
Mariappan et al., 2011; Mock et al., 2015; Shao et al., 2017; Wang et al., 2011b; Xu et 
al., 2013) and influence each other’s stability. Knocking down Bag6 leads to reduced 
cellular levels of TRC35 and Ubl4A (Krenciute et al., 2013), and knocking down both 
TRC35 and Ubl4A results in reduction of Bag6 levels (Krenciute et al., 2013).  
This chapter explores the molecular basis for cytosolic retention of Bag6 by TRC35. Our 
results reveal that the Bag6-TRC35 interface seen in our crystal structure (Fig. 2.7) is 
crucial for cytoplasmic retention of Bag6. Furthermore, this interaction is important for 
maintaining TRC35 stability. Our results, combined with previous human genetics and 
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qualitative mass spectrometry studies, suggest that nucleo-cytoplasmic distribution of 
Bag6 is partially mediated by modulation of Bag6 expression.  
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Results 
Probing the Bag6-TRC35 interface 
To validate the interfaces observed in the Bag6-TRC35 structure (Fig. 2.7), we generated 
alanine mutants for analysis by yeast 2-hybrid analysis. A fragment of Bag6 (residues 951-
1126) was attached to the GAL4 transcription activating domain and full-length TRC35 
was attached to the GAL4 DNA-binding domain. Of the single amino acid substitutions, 
only one residue, TRC35 (Y262A), disrupted the yeast 2-hybrid interaction (Fig. 4.1A). 
The Bag6 mutations W1004A and W1012A are localized at interface I and Y1036A is 
localized at interface II. The combination of the two mutations synthetically disrupted the 
interaction (W1004A/Y1036A or W1012A/Y1036A) (Fig. 4.1D) confirming that both 
interfaces are critical for forming a stable complex between Bag6 and TRC35. Expression 
of Bag6 and TRC35 in the yeast used from two-hybrid experiments was confirmed by 
immunoblotting (Fig. 4.1C).  
We also sought to validate the interaction of TRC35 with full length Bag6 in the context of 
a mammalian cellular environment by co-immunoprecipitation. For this, we co-expressed 
N-terminally GFP-tagged wild-type (wt) Bag6 or the mutants Bag6(W1004A), 
Bag6(W1012), Bag6(Y1036A), Bag6(W1004A/Y1036A), and Bag6(W1012A/Y1036A) 
with FLAG-tagged TRC35 in a Bag6 knock-out 293T cell (Bag6-/-). Bag6 and associated 
proteins were captured from detergent-derived cell extracts by immunoprecipitating using a 
GFP-antibody. Immunoblotting analysis showed that these mutations on full length Bag6 
protein only partially disrupted the interaction: compared to wtBag6 that efficiently 
captured TRC35 (Fig. 4.2 lane 9), the single mutation W1004A reduced but not completely 
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abolished the amount of TRC35 captured by Bag6 (lane 10). This was also true for the 
double mutants (lane 13 &14). 
TRC35 Masks the Nuclear Localization Sequence of Bag6 and Retains Bag6 in the 
Cytosol 
To investigate the Bag6-TRC35 interface in the context of Bag6 localization, the mutants 
identified from yeast 2-hybrid and immunoprecipitation were used for localization studies. 
Overexpression of TRC35 has been shown to retain wtBag6 in the cytosol (Wang et al., 
2011b), suggesting that TRC35 binding is required for cytosolic localization of Bag6. 
Because the mutations identified in our yeast 2-hybrid experiments specifically prevent 
TRC35 binding, we postulated that exogenously expressed Bag6 mutants defective in 
TRC35 binding would localize primarily in the nucleus regardless of TRC35 expression. 
To test this hypothesis, wt and mutant Bag6 were expressed in Cos7 cells with or without 
TRC35•FLAG and the localization of Bag6 and TRC35 was examined by 
immunofluorescence. 
As expected (Wang et al., 2011b), given the NLS, overexpressed wtBag6 and various Bag6 
mutants were localized to the nucleus (Fig. 4.3A). This is likely due to excess Bag6 that 
cannot be retained in the cytosol by endogenous TRC35. Indeed, when TRC35 is co-
expressed with wtBag6, the increased cytosolic pool of TRC35 captures wtBag6 and both 
proteins stain primarily in the cytosol (Fig. 4.3A). In accordance with the 
immunoprecipitation results (Fig. 4.2), introduction of a single mutation—W1004A, 
W1012A, or Y1036A—results in some Bag6 localization to the nucleus (Figs. 4.3B, C, and 
D). Mutations at both interface I (W1004A or W1012A) and interface II (Y1036A) further 
  
87 
reduce binding between Bag6 and TRC35 (Fig. 4.2) and Bag6 localizes primarily to the 
nucleus (Fig. 4.3E and F). These results unequivocally establish TRC35 as a cytoplasmic 
retention factor of Bag6. 
Free TRC35 is Ubiquitylated 
Careful examination of the immunoprecipitation results (Fig. 4.2) revealed two intriguing 
observations: (1) an unexpected increase in TRC35 binding to Bag6 double mutants 
relative to single mutants even though these double mutants contain exposed NLS due to 
lack of TRC35 shielding (Fig. 4.2, compare lanes 11-12 vs. lanes 13-14) and (2) the 
appearance of higher molecular weight products for Bag6 double mutants (Fig. 4.2, 
asterisk). As there is evidence that the stability of TRC35 requires forming a proper 
complex with Bag6 (Krenciute et al., 2013; Mariappan et al., 2010) and given the 
implication of Bag6 as a chaperone holdase in protein quality control processes such as 
mis-localized protein degradation (Hessa et al., 2011) and ER-associated protein 
degradation pathways (Payapilly and High, 2014; Wang et al., 2011b), we postulated that 
TRC35 mutants that fail to form a complex with Bag6 at its physiological binding site are 
unstable and become a target for degradation pathways. This would result in TRC35 
becoming a target for Bag6 dependent degradation leading to TRC35 binding at the Bag6 
substrate-binding site. In this case, the higher molecular weight bands observed in figure 
4.2 would probably be ubiquitylated TRC35 bound to Bag6.  
To verify this hypothesis, Bag6-/- 293T cells were used to co-express TRC35, Bag6 variants 
and ubiquitin with the expectation that destabilized TRC35 would show increased ubiquitin 
complexes. Cells were transfected with TRC35•FLAG, Bag6•GFP, and HA•ubiquitin. 
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Proteins bound to Bag6 were first immunoprecipitated with GFP antibody. To remove 
other ubiquitinated Bag6 substrates (Minami et al., 2010; Wang et al., 2011b; Xu et al., 
2013), the samples obtained from the GFP immunoprecipitation were subject to a second 
round of immunoprecipition using FLAG beads under denaturing conditions. 
Immunoblotting analysis of the samples from the first round of immunoprecipitation 
showed that all Bag6 variants pulled down ubiquitinated proteins, suggesting that these 
mutations did not affect its substrate-binding activity (Fig. 4.4, lane 2-7). Re-
immunoprecipitation with FLAG antibody showed that TRC35 associated with wtBag6 
carried a small amount of ubiquitin conjugates, but those associated with Bag6 variants that 
disrupted physiological association with TRC35 carried significantly more ubiquitin 
conjugates. Compared to single Bag6 mutations, TRC35 bound to the double mutants had 
the highest ubiquitin to TRC35 ratio (Figs. 4.4 compare lanes 10-12 to 13-14) supporting 
the idea that the subset of TRC35 molecules unable to associate with Bag6 via the NLS 
domain are unstable and become targets for ubiquitin-dependent degradation through a 
client-chaperone interaction with Bag6. This suggests that the ubiquitylated TRC35 
associates with the quality control module (QC) of Bag6 (Shao et al., 2017).  
We sought to ensure that TRC35 is a Bag6-QC substrate by investigating the effect of the 
E3 ligase RNF126 on TRC35 ubiquitylation. RNF126 is a Bag6-associated E3 ligase 
utilized by the Bag6-QC for ubiquitylation of Bag6-associated clients in the cytosol 
(Rodrigo-Brenni et al., 2014). Ubiquitylated Bag6-QC substrates are proteasomally 
degraded (Shao et al., 2017). If TRC35 ubiquitylation is mediated by Bag6-QC, knocking 
down RNF126 in cells expressing Bag6 mutants would result in reduced ubiquitylation of 
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TRC35. Furthermore, if ubiquitylated TRC35 is degraded by the ubiquitin proteasome 
system, RNF126 reduction would also stabilize TRC35. To test this hypothesis, the effect 
of RNF126 and proteasome inhibition on TRC35 ubiquitylation and stability were 
examined. 
We first examined the effect of siRNA-mediated RNF126 knockdown on TRC35 
ubiquitylation. 293T cells co-expressing HA•ubiquitin, TRC35•FLAG and either wt or 
mutant Bag6•GFP (W1004A/Y1036A or W1012A/Y1036A) were treated with siRNA 
against RNF126. Changes in ubiquitylation were compared by taking the relative ratio 
between ubiquitylated TRC35 and unmodified TRC35 (Ub-TRC35/TRC35). The ratio in 
cells expressing both wtTRC35 and wtBag6 without RNF126 was defined as 1. In cells 
expressing Bag6 mutants, TRC35 bound to Bag6 is mostly ubiquitylated (Fig. 4.5A lanes 
13 and 14); the relative ratio between ubiquitylated TRC35 (Ub-TRC35) and unmodified 
TRC35 in cells expressing Bag6(W1004A/Y1036A) and Bag6(W1012A/Y1036A) are 193 
and 111, respectively (Fig. 4.5B). Knockdown of RNF126 reduces TRC35 ubiquitylation 
in cells expressing Bag6 mutants, resulting in ~10-20-fold reduction in Ub-TRC35/TRC35 
(Fig. 4.5B). In contrast the Ub-TRC35 to TRC35 ratio in cells expressing wtBag6 remains 
constant (Figs. 4.5A lane 12 & 16 and 4.5B) regardless of RNF126 treatment, suggesting 
that TRC35 that is bound to Bag6 at the native binding site is stable. Both unmodified and 
polyubiquitylated TRC35 is stabilized by proteasome inhibition by MG132 (Fig. 4.5C 
lanes 9 & 10 vs. 11 & 12), confirming that Ub-TRC35 is degraded by the ubiquitin 
proteasome system. The accumulation of unmodified TRC35 (Fig. 4.5C lanes 9 & 10 vs 11 
& 12) is probably due to depletion of free ubiquitin in the cell (Melikova et al., 2006). To 
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better observe the changes in accumulation of Ub-TRC35 upon RNF126 knockdown, cells 
were simultaneously treated with RNF126 siRNA and MG132 to prevent the degradation 
of Ub-TRC35. For both cells expressing wtBag6 and Bag6(W1004A/Y1036A), 
accumulation of ubiquitylated TRC35 was reduced (Fig. 4.6 compare lanes 9 & 10 vs. 11 
& 12). Together these results demonstrate that ubiquitylation of free TRC35 is modulated 
by the quality control role of Bag6 and RNF126.  
TRC35 has higher affinity for Bag6 than Karyopherin-α 2 (KPNA2) 
All molecules destined for the nucleus must move through the nuclear pore complex 
(NPC), a large assembly that spans the nuclear envelope and facilitates nucleo-cytoplasmic 
traffic (Hoelz et al., 2011). Macromolecules larger than ~40 kDa cannot freely diffuse 
through the NPC and require carrier proteins, such as the karyopherin-α (KPNA) and -β 
families of transport receptors (Lange et al., 2007; Pumroy and Cingolani, 2015). The two 
basic clusters, R1024KVK and K1043RRK (Fig. 4.7A), in Bag6 are thought to act as a 
bipartite NLS by specifically recognizing the acidic substrate-binding surface of 
karyopherins (Manchen and Hubberstey, 2001). In HeLa cells, the K1045R to S1045L 
mutation has been shown to abrogate nuclear localization of Bag6 (Manchen and 
Hubberstey, 2001). Therefore, TRC35 and KPNA both bind Bag6 at the fragment that 
contains the NLS although likely distinct residues mediate the respective interactions.  
To confirm that the Bag6-NLS is a KPNA binding site and to define the residues involved 
in KPNA binding, a Bag6 C-terminal 131 residues (Bag6C131) (Wu et al., 2004) in 
complex with hexahistidine-tagged full-length Ubl4A (Bag6C131-6xHis•Ubl4A) was 
purified from E. coli. KPNA2 was chosen specifically as it had been seen to interact with 
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Bag6 (Rouillard et al., 2016) and could be stably purified. Mutations previously shown to 
abrogate Bag6 nuclear localization (Manchen and Hubberstey, 2001) were introduced at 
either the first basic cluster (1024SL) or the second basic cluster (1045SL) (Fig. 4.7A). The 
purified Bag6C131-6xHis•Ubl4A variants were incubated with either GST•TRC35 or 
MBP•KPNA2 (58-529) and the resulting complexes were isolated using Ni-NTA beads. 
GST•TRC35 pulled down wild-type, 1024SL, and 1045SL Bag6C131-6xHis•Ubl4A with 
similar efficiency (Fig. 4.7B lanes 5-7), demonstrating that these residues are not involved 
in binding TRC35. MBP•KPNA2 formed a sufficiently stable complex with Bag6 that can 
be visualized in a pull-down where MBP•KPNA2 captures wtBag6 (Fig. 4.7B lane 9). 
Surprisingly, only mutating of the second basic cluster led to significant disruption of the 
interaction between Bag6C131-6xHis•Ubl4A and MBP•KPNA2 (Fig. 4.7B compare lane 
10 and 11). These results show that the residues required for binding KPNA2 are distinct 
from those required for binding TRC35, and TRC35 acts as a cytosolic retention factor by 
occluding the Bag6 NLS. Moreover, the second basic cluster is necessary and sufficient for 
binding KPNA2. 
If TRC35 binding to Bag6 prevents KPNA-mediated nuclear translocation, only TRC35-
free Bag6 should be able to bind KPNA and be translocated to the nucleus. There are 
several ways in which this could be achieved. One such is that if KPNAs have a higher 
affinity for Bag6 than TRC35, upregulation of KPNA expression would lead to 
displacement of TRC35 from Bag6 and formation of a Bag6-KPNA complex. To test this, 
we sought to compare the binding affinities of the TRC35 and KPNA2 to Bag6 using an 
exchange assay. Bag6C131-6xHis•Ubl4A complexes with GST•TRC35 were generated 
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and bound to glutathione affinity resin beads via the GST-tag. After washing, varying 
amounts of MBP•KPNA2 were added to the bound beads. The ability of MBP•KPNA2 to 
displace Bag6C131-6xHis•Ubl4A from GST•TRC35 was determined by the amount of 
Bag6C131-6xHis•Ubl4A that was eluted from the resin after incubation. In this case, even 
at the highest concentration tested (2x molar excess), there was no significant displacement 
of Bag6 from TRC35 by KPNA2 (Fig. 4.8 lanes 4-7). Performing the opposite experiment, 
starting with MBP•KPNA2-Bag6C131-6xHis•Ubl4A on amylose beads, adding excess 
GST•TRC35 resulted in the dissociation of the MBP•KPNA2-Bag6C131-6xHis•Ubl4A 
complex (Fig. 4.8 lanes 11-14). These results highlight the stability of the TRC35-Bag6 
complex and argue against the ability of KPNA regulation as a means for modulating the 
nuclear pool of Bag6. 
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Discussion 
Bag6 is a critical scaffolding factor that has important nuclear and cytosolic roles. It is 
unclear how the localization of Bag6 is regulated. Here we report biochemical and cell 
biological characterization of the Bag6-TRC35 complex and suggest a mechanism for 
regulation of Bag6 localization. 
Our results demonstrate that TRC35 acts as an intermolecular mask to the monopartite 
Bag6 NLS in a role similarly performed in other pathways. Examples of other cytosolic 
retention factor pairs include IκB and NF-κB (Beg et al., 1992), HIC and Rev (Gu et al., 
2011) and BRAP2 that retains HMG20A (Davies et al., 2013). Unlike other cytoplasmic 
retention factors, which have only been shown to bind their target NLS-containing proteins 
for occlusion of the NLS, TRC35 also plays a distinct role in the cytoplasmic TA targeting 
and protein quality control when in complex with Bag6. This dual functionality seems to 
have been evolutionarily conserved. One study showed that Ubl4A also has a nuclear role 
of promoting STAT3 dephosphorylation (Wang et al., 2014b). This study did not explore 
the localization of Bag6 relative to Ubl4A, but Bag6 that translocates to the nucleus brings 
Ubl4A with it (Krenciute et al., 2013). In yeast, fungal Get4 binds the N-terminal domain 
of Get5, which appears to contain a functional NLS that directs Get5 to the nucleus during 
a ‘Get5-mediated stress response’ (Arhzaouy and Ramezani-Rad, 2012).  
These results allow speculation of possible regulatory mechanism for Bag6 nuclear 
localization. First, disrupting the Bag6-TRC35 interface by introducing alanine mutations 
results in Bag6 and RNF126-dependent ubiquitylation and degradation of TRC35 (Fig. 
4.4). Similarly, knocking down Bag6 has been shown to reduce le
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cells (Krenciute et al., 2013), demonstrating that Bag6 is required for TRC35 stability. We 
also show that KPNA2 has a lower affinity for Bag6 than TRC35 (Fig. 4.8B), which 
suggests that for Bag6 to bind KPNA and translocate into the nucleus, it needs to be free of 
TRC35. The most likely explanation is that cells regulate Bag6 localization by modulating 
Bag6 levels or decreasing TRC35 levels. In humans, Bag6 rs3117582 single nucleotide 
polymorphism at the promoter region of Bag6, likely affecting expression levels, is 
associated with higher incidence of lung cancer (Chen et al., 2014; Etokebe et al., 2015b; 
Zhao et al., 2014) and osteoarthritis (Etokebe et al., 2015a). The localization could also be 
pre-translationally regulated with differential splicing. In brain and breast tissue, for 
instance, Bag6 isoforms that lack the NLS are expressed at higher levels than isoforms with 
the NLS (Luce et al., 2016).  
TRC35 utilization of the Bag6 quality control module has important implications on 
previous Bag6 knockdown studies. When Bag6 is knocked down TRC35 protein levels, not 
mRNA levels, decrease (Krenciute et al., 2013). Thus, when Bag6 is knocked down, 
TRC35 translation probably continues. Knocking down Bag6 then not only eliminates 
Bag6 localization to the nucleus due to higher TRC35 to Bag6 ratio, but also affects the 
quality control module of Bag6 because excess TRC35 would become Bag6 substrates. 
The combination of these effects perhaps explains the pleiotropic effects of Bag6 reduction 
or removal from cells.    
Our biochemical studies unequivocally establish TRC35 as a cytosolic retention factor of 
Bag6 and suggest that Bag6 needs to be in excess for nuclear localization. However, how 
  
95 
different cell types regulate Bag6 localization, whether the TRC35-dependent regulation 
can be mediated by specific stress, and the biological implications of differential 
distribution of Bag6 are important questions for future studies. 
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Figures 
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Figure 4.1. Validation of the Bag6-TRC35 interface 
(A) Yeast 2-hybrid assay to validate the interface identified in the crystal structure. Wild-
type or mutant full length TRC35 conjugated to the DNA binding domain was expressed 
with wild-type Bag6(951-1126) conjugated to the transcription activating domain. 
Transformation was confirmed by ability to grow on SC-Ura-Leu media. Interaction was 
determined by ability to grow on SC-Ura-Leu-Ade media. (B) Wild-type full-length 
TRC35 conjugated to the DNA binding domain was expressed with wild-type or mutant 
Bag6(951-1126) conjugated to the transcription activating domain. (C) Expression of 
TRC35 and Bag6 in yeast cells used from yeast 2-hybrid was examined by Western blot. 
Antibodies against Gal4 DNA binding domain or trans-activating domain were used to 
detect expression of Gal4BD-TRC35 and Gal4AD-Bag6. (D) Combination of mutations at 
interface I (W1004A and W1012A) and interface II (Y1036A) is sufficient for disrupting 
yeast 2-hybrid interaction.  
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Figure 4.2. Validation of Bag6-TRC35 interface in mammalian cells 
Wild-type or mutant Bag6•GFP was co-expressed in Bag6-/- 293T cells with TRC35•FLAG 
and immunoprecipitated using anti-GFP antibody. Amount of TRC35 retrieved by Bag6 
was assessed by blotting with anti-FLAG antibody. The position of the higher molecular 
weight TRC35•FLAG is highlighted with an asterisk.  
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Figure 4.3. Bag6 mutations at the TRC35 binding site results in nuclear localization of 
Bag6 
(A-F) Cos7 cells were transfected either with Bag6•GFP (wt or mutant) expressing 
plasmid alone or co-transfected with TRC35•FLAG (wt) expressing plasmid. Cells were 
stained with anti-GFP (green) and/or anti-FLAG (red) antibodies. DNA was stained with 
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DAPI where indicated (blue). In the Bag6 column, the percent of Bag6 calculated to be 
in the nucleus is noted. Shown are representative cells imaged by a confocal microscope.  
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Figure 4.4 Ubiquitylation of TRC35 upon mutant Bag6 expression 
(A) Immunoprecipitation (IP) of TRC35 in Bag6-/- 293T cells co-transfected with plasmids 
encoding TRC35•FLAG (wt), Bag6•GFP (wt or mutants), and HA•ubiquitin. Anti-GFP 
antibody was used for the first IP. Anti-FLAG antibody was used for the second IP in 
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denaturing conditions.  TRC35 ubiquitination was assessed by immunoblotting with anti-
HA antibody. The exposure times were adjusted to improve visibility of the reactive bands. 
(B) IP was carried out as in (A) in Bag6-/- 293T cells co-transfected with plasmids encoding 
TRC35•FLAG (wt) and Bag6•GFP (wt or mutants). TRC35 ubiquitination was assessed by 
immunoblotting with anti-FLAG antibody. The exposure times were adjusted to improve 
visibility of the reactive bands. (C) The cell extract used for immunoprecipitation was 
immunoblotted for Bag6, TRC35, and ubiquitin with Bag6 antibody, FLAG antibody and 
HA antibody, respectively. 
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Figure 4.5 RNF126 knockdown stabilizes TRC35 in cells expressing mutant Bag6 
(A) wt293T cells expressing TRC35•FLAG, Bag6•GFP and HA•ubiquitin were treated 
with siRNA against RNF126. Cells were lysed and TRC35 bound to Bag6 were 
immunoprecipitated first with GFP antibody then with FLAG antibody in denaturing 
condition. The amount of TRC35 and ubiquitylated TRC35 was assessed by 
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immunoblotting with anti-TRC35 antibody and anti-HA antibody, respectively. (B) The 
relative amounts of ubiquitylated TRC35 and unmodified TRC35 from figure 4.5 are 
calculated as a ratio. (C) 293T cells expressing wtTRC35•FLAG, Bag6•GFP (wt or 
W1004A/Y1036A) and HA•ubiquitin were treated 10 µM MG132. Bag6 and TRC35 were 
immunoprecipitated and immunoblotted as in A.  
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Figure 4.6 TRC35 ubiquitylation is dependent on RNF126. 
wt293T cells co-transfected with plasmids encoding TRC35•FLAG (wt), Bag6•GFP (wt or 
mutants), and HA•ubiquitin. The cells were simultaneously treated with MG132 and 
siRNA against RNF126. The cell extracts were subject to two rounds of denaturing 
immunoprecipitation with anti-GFP antibody then with anti-FLAG antibody. TRC35 
ubiquitylation was assessed by immunoblotting with HA antibody.  
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Figure 4.7 Biochemical identification of the monopartite Bag6 NLS 
(A) The putative bipartite nuclear localization sequence of Bag6. The serine and leucine 
mutations introduced in this study are highlighted. (B) Recombinantly purified Bag6C131-
6xHis•Ubl4A was incubated with excess GST•TRC35 or MBP•KPNA2 for 20 minutes at 
room temperature. Ni-NTA beads were used to capture purified Bag6C131-6xHis•Ubl4A 
and bound factors. 
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Figure 4.8 TRC35 binding precludes karyopherin α binding to Bag6 
Recombinantly purified Bag6C131-6xHis•Ubl4A was first incubated with either 
GST•TRC35 or MBP•KPNA2. The resulting GST•TRC35-Bag6C131-6xHis•Ubl4A 
complex was incubated with glutathione resin beads, and increasing amounts of 
MBP•KPNA2 was added. The ability of MBP•KPNA2 to displace Bag6C131-
6xHis•Ubl4A from GST•TRC35 was examined by eluting the GST•TRC35 and bound 
Bag6C131-6xHis•Ubl4A from the glutathione resin. The opposite experiment was also 
carried out using amylose resin beads. 
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Materials and Methods 
Expression and purification 
The plasmid containing human KPNA2 was obtained from Addgene (#26677). A 
truncated KPNA2 (58-529) was subcloned into pMAL-C2 vector (New England Biolabs) 
and transformed into E. coli NiCo21(DE3). The cells were grown in 2×YT media and 
induced at 37 °C until OD600 = 0.1 then cooled on ice for 1 hour. Expression was 
induced with 500 µM IPTG for 18 hours at 16°C in a shaking incubator at 200 rpm. The 
cells were harvested as above and resuspended in 50 mM Mops (pH 7.2), 300 mM 
K•glutamate, 5 mM β-mercaptoethanol, supplemented with cOmplete EDTA-free 
protease inhibitor cocktail (Roche) and lysed using the M-110L microfluidizer by two 
passes at approximately 17,500 psi. The lysate was clarified by centrifugation at 235,000 
×g in a Beckman Ti45 rotor for 30 minutes at 4°C. The lysate was incubated for 1 hour 
with 3 mL of a 50% (vol/vol) slurry of amylose resin (New England Biolabs) by rocking. 
The mix was poured into a gravity column then washed with 100 mL lysis buffer. The 
protein was eluted with 12 mL elution buffer (20 mM Mops (pH 7.2), 150 mM 
K•glutamate, 10 mM maltose, 5 mM β-mercaptoethanol). The sample was placed in 
snakeskin dialysis bag (10 kDa cutoff, Thermo Fisher) and dialyzed overnight at 4 °C in 
20 mM Mops (pH 7.2), 50 mM - 800 mM K•glutamate gradient, 5 mM β-
mercaptoethanol. The fractions containing the protein (~36 - 70 mL) were pooled and 
dialyzed in snakeskin dialysis bag in 20 mM Mops (pH 7.2), 50 mM K•glutamate, 5 mM 
β-mercaptoethanol for 2 hours at 4 °C. The sample was concentrated to 2 mL, filtered 
with a 0.22 µm syringe filter, and purified by size-exclusion chromatography over a 120 
mL Superdex 200 column (GE Healthcare) (20 mM Mops (pH 7.2), 50 mM K•glutamate, 
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5 mM β-mercaptoethanol). Fractions containing the sample (60 mL – 90 mL) were 
pooled and concentrated with centrifugal filtration units with 50 kDa molecular weight 
cutoff. 
For expression and purification of GST•TRC35, full-length TRC35 was subcloned into 
pGEX6P-1 (GE Healthcare) and transformed into NiCo21(DE3). The cells were grown at 
37 °C until OD600 = 0.1, chilled on ice for 1 hour, then induced with 500 µM IPTG at 16 
°C for 18 hours in a shaking incubator at 200 rpm. Cells were lysed using 10 mL per g 
cell pellet lysis buffer (50 mM Hepes (pH 7.2), 400 mM KCl, 5 mM mercaptoethanol) 
and incubated with 3 mL 50% (vol/vol) slurry of glutathione resin (GE healthcare) for 2 
hours at 4 °C by rocking. The resin was washed with 100 mL lysis buffer and the protein 
was eluted with 12 mL of freshly prepared 20 mM Hepes (pH 7.2), 150 mM KCl, 33 mM 
glutathione, 5 mM β-mercaptoethanol. The sample was placed in snakeskin dialysis bag 
(10 kDa cutoff, Thermo Fisher) and dialyzed overnight at 4 °C in 20 mM Hepes (pH 7.2), 
100 mM K•glutamate, 5 mM β-mercaptoethanol, before concentration with centrifugal 
filter unit (50 kDa molecular weight cutoff, Millipore). 
Yeast Two-Hybrid 
The PJ69-4α strain was obtained from the Yeast Resource Center at the University of 
Washington. Bag6 isoform b residues 951 to 1126 were cloned into pGAD-C1 vector and 
TRC35 was cloned into pGBDU-C1 vector. Alanine mutations were made using Q5 site-
directed mutagenesis (New England Biolabs). pGAD-C1-TRC35 (wt or mutant) and 
pGBDU-C1-Bag6 (wt or mutant) were co-transformed into PJ69-4α using previously 
described methods (12) and then plated onto SC-Ura-Leu plates and incubated at 30 °C. 
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Single colonies from the transformants were cultured in 5 mL SC-Ura-Leu liquid media 
and grown overnight in a shaking incubator (Multitron Standard Infors HT) at 200 rpm at 
30 °C. 2 × 107 cells were transferred into total 5 mL SC-Ura-Leu media and grown in a 
shaking incubator at 30 °C at 200 rpm for 6 hours. Cells were harvested by centrifugation 
with a Beckman SX4750A rotor at 3000 ×g at 25 °C. The cells were washed twice by 
resuspension in 5 mL sterile water followed by centrifugation at 3000 ×g at 25 °C. After 
the second wash, cells were resuspended in 1 mL sterile water. Concentration was 
measured and 1 × 107 cells were resuspended in total 40 µL of sterile water. 4 µL of this 
resuspended sample were spot plated onto SC-Ura-Leu-Ade plate and incubated for 72 
hours at 30 °C. 
Yeast Two-hybrid Expression Controls 
Cells were grown overnight in SC-Ura-Leu medium. 2.5 x 107 cells were transferred to a 
total 5 mL media and grown for ~6-8 hours until OD600 = 2.0. Cells were harvested by 
centrifugation at 4000 ×g for 5 minutes at 4 °C. Cells were resuspended in 2 mL 10 mM 
TE buffer (Tris-HCl, pH 8.0, 0.1 mM EDTA). Cells were centrifuged in a microcentrifuge 
at 13,500 ×g at 4 °C for 2 minutes. ~37.5 µL glass beads (415-600 µm size) for each OD 
unit were added to the sample. Same volume of 1x SDS-PAGE loading buffer was added. 
The cells were vortexed and immediately plunged into a boiling water bath. After boiling 
for 3 minutes, tubes were immersed into an ice bucket. The tubes were placed into FastPrep 
(MP biomedicals) homogenizer at 6 m/s for 45 seconds. Cells were boiled for 3 minutes 
and centrifuged in a microcentrifuge for 2 minutes at 13,500 g at room temperature. 
Supernatant was transferred to a clean microfuge tube and loaded onto 5-20% gradient gel 
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(Biorad). The protein was transferred onto PVDF membrane. Membrane was blocked with 
Odyssey TBS blocking buffer (Li-Cor) for 1 hour. The membrane was incubated with 
primary antibody against Gal4 DNA binding domain (for TRC35 detection) or Gal4 trans-
activating domain (for Bag6 detection). After washing with TBST (20 mM Tris-HCl, pH 
7.5, 150 mM NaCl, 0.2% Tween-20) for 10 minutes 3 times, membrane was incubated with 
anti-mouse secondary antibody (IRDye 680RD or 800CW, Li-Cor) for 1 hour at room 
temperature. Membrane was washed 3 times with TBST for 10 minutes each. Proteins were 
detected using an Odyssey Imaging System (Li-Cor).  
 
Immunoprecipitation from 293T cells 
On day 0, 5 x 105 Bag6-/- cells were seeded in plates. On day 1, TRC35 with a C-terminal 
FLAG tag (TRC35•FLAG), Bag6 with a C-terminal GFP tag (wt or mutant Bag6•GFP), 
and HA•ubiquitin were co-transfected. On day 3, cells were collected and washed with 1 
mL of ice cold phosphate-buffered saline. The cells were lysed with NP40 lysis buffer 
containing 1 mM N-ethylmaleimide to inhibit the ubiquitin-proteasome system. The 
detergent soluble fraction was used for immunoprecipitation (IP) using GFP antibody. 
After IP, the beads were divided into two fractions. Half was analyzed directly with SDS-
PAGE and immunoblotting with indicated antibodies to assess the interaction between 
TRC35 and Bag6 and Bag6 mutants. The other half was used for denaturing 
immunoprecipitation to detect TRC35 ubiquitylation. The beads were resuspended in 150 
µL denaturing buffer (1× PBS, 1% SDS, 5 mM DTT) and heated at 95 °C for 10 minutes.  
Then 1.35 mL NP40 lysis buffer was added into the tube and incubated at 4 °C for 30 
minutes. The supernatant was used for immunoprecipitation with FLAG antibody 
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conjugated M2 beads (Sigma-Aldrich). The eluate was analyzed with SDS-PAGE and 
immunoblotting.  
 
For RNF126 knockdown, 5 × 105 wild type 293T cells were seeded in 6 well plates. On 
day 1, cells were transfected with 60 pmol RNF126 siRNA (Thermo Fisher) or control 
siRNA using Lipofectamin RNAiMAX (Thermo Fisher). The sequence of the RNF126 
siRNAs are GCAUCUUCGAUGACAGCUU (catalog number S31185), 
GAUUAUAUCUGUCCAAGAU (catalog number S31186), and 
GCAGGGCUACGGACAGUUU (catalog number S13387). Cells were passaged in 1:2 
ratio onto new plates on day 2. Cells were transfected with TRC35•FLAG (wt), Bag6•GFP 
(wt or mut) and HA•ubiquitin on day 3. On day 4, the cells were collected and cell extracts 
were assayed with sequential immunoprecipitation and immunoblotting as above. To assay 
TRC35 ubiquitylation after proteasome inhibition, 5 × 105 wild type 293T cells were 
seeded in plates on day 0. On day 1, cells were transfected as above. 24-hours post 
transfection, proteasome inhibitor, MG132, was added to the concentration of 10 µM and 
incubated overnight. Cells were collected and analyzed with sequential 
immunoprecipitation and immunoblotting as above. 
 
To investigate the effect of simultaneous RNF126 down-regulation and proteasomal 
inhibition on TRC35 ubiquitylation, 5 × 105 Bag6 293T cells were seeded in plates on day 
0. On day 1, cells were transfected with RNF126 siRNA or control siRNA. On day 2, cells 
were split in half into new plates. After ~9 hours, plasmids encoding TRC35•FLAG (wt), 
Bag6•GFP (wt or mutant) and HA•ubiquitin were transfected. On day 3, medium was 
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replaced with fresh medium containing either 10 µM MG132 or DMSO. On day 4, cells 
were collected and sequential IP was performed as described above.  
 
Localization assay 
On day 0, 1 × 105 Cos7 cells were seeded onto a 12-well plate with a poly-D-lysine 
coated cover glass. After approximately 8 hours, the cells were co-transfected with 
TRC35•FLAG and Bag6•GFP (wt or mutant). 20 hours after transfection, the cells were 
washed with 1× PBS, fixed with 4% (vol/vol) paraformaldehyde for 15 minutes, then 
washed with 1× PBS before permeabilization with staining solution (1× PBS, 5% fetal 
bovine serum (vol/vol), 0.1% (vol/vol) NP40 with primary and secondary antibodies). 
The staining solution was replaced with staining solution with FLAG antibody and 
incubated at room temperature for 1 hour. After washing the cells with 1× PBS, the cells 
were incubated with staining solution with secondary antibody then washed with 1× PBS. 
Cells were counterstained with a mounting medium containing DAPI to illuminate the 
nucleus. Cover glass was mounted for visualization with Axiovert 200M microscope 
(Zeiss). 
To assay the localization of Bag6, 3 view fields were evaluated suing an Axiovert 200 
inverted microscope equipped with a 40x oil immersion objective. Confocal analyses 
were performed with a Zeiss LSM 780 system. Approximately 100 cells were counted for 
each constructed tested. The localization of Bag6 in the nucleus was assessed visually 
and cells were categorized as either Bag6 out of nucleus or Bag6 inside the nucleus.  
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In vitro binding assay with purified proteins 
nmol hexahistidine-tagged Ubl4A-Bag6C131 (wt, 1025SL or 1043SL) was incubated 
with 1 nmol GST•TRC35 or 1 nmol MBP•KPNA2 in 100 µL total volume of binding 
buffer (20 mM Mops (pH 7.2), 100 mM K•glutamate 20 mM imidazole, 5 mM β-
mercaptoethanol) at room temperature for 30 minutes. 30 µL 50% slurry of Ni-NTA 
beads (Qiagen) equilibrated with binding buffer were added to the reaction and incubated 
at room temperature for 30 minutes. The beads were resuspended using a pipet every 10 
minutes. The beads were then washed twice with 100 µL room temperature binding 
buffer. Samples bound to the resin were eluted with 25 µL elution buffer (20 mM Mops 
(pH 7.2), 100 mM K•glutamate, 300 mM imidazole, 5 mM β-mercaptoethanol) and 
evaluated with Coommassie-stained SDS-PAGE gel. 
Exchange assay 
1 nmol hexahisidine-tagged Ubl4A-Bag6C131 (wt, 1024SL, or 1043SL) was incubated 
with 1 nmol GST•TRC35 in 100 uL total volume of binding buffer (20 mM Mops (pH 
7.2), 100 mM K•glutamate, 20 mM imidazole, 5 mM β-mercaptoethanol). 30 µL 50% 
(vol/vol) slurry of glutathione beads (GE Healthcare) equilibrated with binding buffer 
were added to the reaction and incubated at room temperature for 30 minutes. The beads 
were resuspended every 10 minutes. The beads were washed twice with 100 µL room-
temperature binding buffer (20 mM Mops (pH 7.2), 100 mM K•glutamate, 5 mM β-
mercaptoethanol), and then 0.5, 1 or 2 nmol MBP•KPNA in 100 µL was added to the 
resin and incubated for 30 minutes at room temperature. The beads were washed twice 
with 100 µL binding buffer and then eluted with 25 µL elution buffer (20 mM Mops (pH 
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7.2), 100 mM K•glutamate, 33 mM glutathione, 5 mM β-mercaptoethanol). The reverse 
experiment starting with hexahistidine-tagged Ubl4A-Bag6C131 and MBP•KPNA2 was 
carried out as above but using 30 µL 50% (vol/vol) slurry of amylose beads (New 
England Biolabs) in 20 mM Mops (pH 7.2), 100 mM K•glutamate, 5 mM β-
mercaptoethanol and eluted with 25 µL of 20 mM Mops (pH 7.2), 100 mM K•glutamate, 
10 mM maltose, and 5 mM β-mercaptoethanol. 
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C h a p t e r  6  
BAG6: A MODULAR MULTITASKER 
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Concluding Remarks  
Initial appreciation of the unique nature of Bag6 as a component of the TA targeting 
machinery led to two major questions that this dissertation seeks to address. The first 
question pertains to the difference in the molecular architecture between the fungal Get4-
5 and the mammalian Bag6-TRC35-Ubl4A sorting complexes. Atomic resolution crystal 
structures presented in this study reveal surprising degree of structural conservation. 
Although the incorporation of Bag6 results in overall reorganization—from a 
heterotetramer to a heterotrimer—the structural elements crucial for protein-protein 
interactions between the TA targeting components have all been conserved (Fig. 5.1). 
Accordingly, the trimeric Bag6 complex for TA sorting is functional equivalent to the 
Get4-5 sorting complex.  
Importantly, the architectural reorganization leads to changes in stoichiometry. In the 
fungal system, the heterotetramer of Get4-5, which contains two copies of both Get4 and 
two Get5, could bring together two dimers of Get3, ultimately forming a Get3 tetramer. 
In the mammalian system, the sorting complex includes one TRC35 and one Ubl4A, 
which bind a single dimer of TRC40 (Fig. 5.1). Homo-oligomerization of Bag6 has been 
observed in vitro (Xu et al., 2013), but it is unclear whether this oligomeric complex is 
physiologically relevant. Similarly, physiological relevance of the Get3 tetramer is under 
debate in the field. Several lines of evidence support the existence of a tetrameric Get3. 
First, a crystal structure of a tetrameric archaeal homologue of Get3 has been solved 
(Suloway et al., 2012). Second, recombinantly expressed Get3-TA complex purifies as a 
tetramer (Bozkurt et al., 2009; Suloway et al., 2012) and is competent for in vitro TA 
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insertion into purified microsomes (Suloway et al., 2012). Third, Get3 tetramerization 
stimulates its ATPase activity by ~100 fold (Rome et al., 2013). However, the only 
atomic resolution structure of a Get3-TA complex solved thus far suggests that dimeric 
Get3 (Mateja et al., 2015) is sufficient for binding and targeting TA proteins. It should be 
noted that the crystallized Get3-TA complex was artificially stabilized by (1) introducing 
a mutation that rendered Get3 incompetent for ATP hydrolysis and (2) adding high-
affinity synthetic antibody fragments. As a result, the crystal structure could have trapped 
and captured a specific intermediate or an artificial state of the Get3-TA complex. 
Whether tetrameric Get3/TRC40 plays a physiological role in TA targeting remains to be 
seen.  
Ultimately, the observation that the C-terminal TA targeting module—the minimal Bag6 
complex—characterized in this study is structurally and functionally equivalent to the 
fungal Get4-5 complex begged the question: what different purpose, if any, does Bag6 
serve? 
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Figure 5.1 Cartoon summary of the fungal and metazoan sorting complexes. Left: fungal Get4-5 TA sorting 
complex and its binding partners, Sgt2 and Get3, are illustrated. Right: metazoan Bag6 TA sorting complex and its 
binding partners, SGTA and TRC40, are illustrated. The structurally conserved dimerization domains, whose structures 
have been solved in this study, are highlighted with grey and yellow dotted boxes.  
One purpose Bag6 serves is to physically couple protein targeting and quality control. A 
recent study demonstrated that purified N-terminal domain of Bag6 (Fig. 5.2), which 
excludes the TA targeting module, is sufficient for substrate ubiquitylation (Shao et al., 
2017). Bag6 seems to decide the fate of TA substrate as it is handed off from SGTA by 
utilizing either its C-terminal targeting module for productive synthesis of well-folded 
proteins or its N-terminal quality control module for degradation of misfolded proteins. 
Such coordination, enabled by modularity, likely minimizes the risk of aggregation for 
nascent TA proteins.  
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Figure 5.2 Summary of Bag6 domains and binding partners. (a) The Bag6 complex is a scaffold for a broad range 
of activities. (a) A model of the Bag6 complex and its defined interactions. For Bag6, the locations of the ubiquitin-like 
domain (UBL), proline-rich domain (PR), domain of unknown function (DUF), nuclear localization sequence (NLS), 
and the BAG domain (pink) are shown. Arrows indicate the five fragments of Bag6 (A, B, C, D, E) used in this study. 
Regions required for interaction with Rpn10c, BORIS, PXT1, and NKp30 are indicated in black lines. The regions 
required for binding of hydrophobic substrates and polyubiquitylated defective ribosomal products (DRiPs) are 
displayed in orange. The region required for Bag6 dimerization is indicated on top. Proteins with defined interactions 
are shown as colored boxes. Bag6-UBL binding proteins are highlighted in yellow. The membrane-embedded UbxD8 
and transmembrane protein gp78 are thought to anchor the Bag6 complex to the ER. Rpn10c is a component of the 
proteasome. For the Bag6 complex, TRC35 (dark red) and Ubl4A (green) are shown with their domains indicated. (b) 
Amino acid sequence of the Bag6 isoform used in this study. Key structural elements are highlighted in unique colors. 
The demonstrated nuclear localization of Bag6 may also be an important functionality 
conferred by Bag6 incorporation. Our structural and biochemical characterization of the 
Bag6-TRC35 complex unequivocally establishes TRC35 as the cytoplasmic retention 
factor for Bag6. While the exact function of Bag6 in the nucleus remains to be seen, cell-
cycle dependence of the nucleo-cytoplasmic distribution of Bag6 (Yong and Wang, 2012) 
and observations of endogenous Bag6 localization in the nucleus (Krenciute et al., 2013; 
Wang et al., 2011b) suggest that nuclear localization of Bag6 is physiologically relevant. 
Furthermore, our exchange assay demonstrated that excess Bag6 relative to TRC35 is 
required for nuclear translocation. In fact, estimated physiological ratio of Bag6 to 
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TRC35 in HeLa cells as determined by qualitative mass spectrometry is 1.2 (Kulak et al., 
2014). We postulate that the relative protein abundance of Bag6 and TRC35 is fine-
tuned, in which Bag6 acts as a stoichiometry sensor. TRC35 levels would be interpreted 
as a signal for Bag6 to localize to the nucleus. As such, results presented here necessitate 
re-interpretation of a large body of work in the field that investigated the localization of 
Bag6 independent of TRC35 and Ubl4A.  
Our interest in Bag6 began in the context of membrane protein biosynthesis. Bag6, 
however, is a multifaceted protein that regulates diverse cellular processes in complex 
multicellular animals. Its modularity demonstrates the benefits of modular protein 
structure in coordinating cellular signals.  
Juxtaposition of functional modules leads to physical proximity and coupling, resulting in 
efficiency. In the case of Bag6, it reduces the amount of time that a failed nascent 
substrate would spend in the cytosol. The incorporation of Bag6 in metazoans suggests 
that in higher eukaryotes, the cost of misfolded protein and potential aggregation is 
higher than it is in fungi.  
Modularity also allows for additional fine-tuning of protein function via alternative 
splicing. Due to the modular nature of Bag6 protein function, the Bag6 gene can generate 
multiple proteins with varying combinations of functional modules. Of the ~20 predicted 
Bag6 isoforms documented on the NCBI database, 7 are missing the BAG domain 
identified in this study. Bag6 that lacks Ubl4A would not be competent for TA handoff, 
but its quality control module remains intact (Shao et al., 2017) (Fig. 3.7). Its shortest 
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predicted isoform is 903 residues long and is missing a large portion of the second 
proline rich domain (Fig. 5.2). Analysis of RNA-seq data from the Illumina Human Body 
Map Project revealed that Bag6 transcripts without NLS are abundant in breast and brain, 
while transcripts with NLS are abundant in liver, lung, testes, prostate, kidney and lymph 
nodes (Luce et al., 2016). In rats, different Bag6 isoforms are expressed in distinct 
developmental stages (Kwak et al., 2008). Thus, in addition to the modulation of TRC35 
expression, alternative splicing would affect Bag6 localization and function. The 
functional and physiological consequence of different Bag6 isoforms, however, is unclear 
and is a question for future studies.  
Recent structural and biochemical breakthroughs have led to rapid leaps in our 
understanding of TA targeting and Bag6, but challenging questions remain. Is the 
Get3/TRC40 tetramer physiologically relevant? Does Bag6 change the stoichiometry of 
TRC components in metazoans? How is TRC35 expression, and Bag6 localization, 
modulated? Could some of the pleiotropic effects of knocking down Bag6 be explained 
through the resulting destabilization of TRC35? A multifaceted approach that combines 
structural and mechanistic characterization of Bag6 with cell biological and organismal 
studies is required for a complete understanding of this fascinating protein.  
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